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ABSTRACT 
_____________________________________________________________________
Mitochondrial mutations and heteroplasmy have been associated with disease states 
that result from inadequate cellular energy production. As mitochondrial DNA 
(mtDNA) encodes many of the polypeptides involved in oxidative phosphorylation 
(OXPHOS), mtDNA mutations may lower energy production which is required for 
cell division and sustained ATP synthesis. In order to test the relationship between 
mtDNA mutations and the rate of cell division, a mammary epithelial cancer cell line, 
MCF-7, is used as a model. Nine proliferate single cell clones have been isolated from 
MCF-7. Population doubling times of six single cell clones and the MCF-7 stock have 
been determined. Clones with distinctly different growth rates were selected for 
mutational analysis. Growth rates of these clones appeared to be different from each 
other. Using polymerase chain reaction (PCR) and DNA sequencing, three cases of 
heteroplasmy have been identified in the mitochondrial genes of the MCF-7 stock and 
four single cell clones (ATPase C9119T, ND6 T14300G, Cytb G15807A). 
Heteroplasmy present in the Cytb gene is differs between single cell clones. 
Differences between the growth rates may be indicative of metabolic variations in 
these single cell clones. The OXPHOS enzymes encoded by the mutated genes were 
quantified by standard enzymatic assays. The assays demonstrated significant 
differences in specific activity between the clones, but were not correlated with 
mitochondrial heteroplasmy. This thesis determines that the differences in specific 
activity observed between clones is of nuclear origin.  
 
 
 
 
i 
CONTENTS 
_____________________________________________________________________ 
INTRODUCTION         1 
The Mitochondria         2 
Energy Conversion Pathways        3 
Reactive Oxygen Species        10 
Mitochondrial Mutation and Disease       15 
The MCF-7 Cell Line as a Model       20 
Thesis Aspirations         21 
 
MATERIAL AND METHODS       22 
Materials          24 
Methodology          24 
Cell Culture          24 
DNA Analysis         30 
Oxidative Phosphorylation        37 
Free Radical Generation        41 
 
RESULTS          46 
Cell Culture          47 
DNA Analysis         55 
Oxidative Phosphorylation        63 
Reactive Oxygen Species        72 
 
DISCUSSION         82 
MCF-7 Growth Characteristics       83 
Mitochondrial DNA Modification and OXPHOS     86 
Reactive Oxygen Species in Cultured Cells      95 
Future Aspirations         100 
Conclusions          101 
 
REFERENCES         103 
 
APPENDIX A 
Abbreviations 
 
APPENDIX B 
Chemical Suppliers 
 
APPENDIX C 
PCR and Sequencing 
 
ACKNOWLEDGEMENTS 
iii 
List of Figures 
 
1.1 The Human Mitochondrion       2 
1.2 The Mitochondrial Genome       3 
1.3 Simplified Schematic of Glycolysis      4 
1.4 The Tricarboxylic Acid Cycle      5 
1.5 The Respiratory Chain       7 
1.6 Nucleic Acid Damage Mediated by the Hydroxyl Radical   11 
1.7 The Neutralization of Hydrogen Peroxide     15 
 
2.1 Cell Culture Equipment       25 
2.2 WST-1 Reagent Reaction       29 
 
3.1 Single Cell Clone Isolation       47 
3.2 Cultures of Established Single Cell Clones     48 
3.3 Population Growth Curve, D9 and D4     50 
3.4 Population Growth Curve, E1 and G8     50 
3.5 Population Growth Curve, B5 and C12     51 
3.6 The WST-1 Assay        52 
3.7 WST-1 Growth Curve of Clones E1 and G8     53 
3.8 WST-1 Growth Curve of Clones B5 and C12    53 
3.9 Comparison of Trypan Blue and WST-1 PDT    55 
3.10 Isolated Cell Culture DNA       55 
3.11  PCR of the ND6 Gene       60 
3.12 C12 ABI Chromatograph of the ND6 Gene     60 
3.13 PCR of the ATPase6 Gene       61 
3.14 ABI Chromatographs of the ATPase6 Gene     61 
3.15 PCR of the Cytb Gene       61 
3.16 ABI Chromatograph of the Cytb Gene, B5     62 
3.17 ABI Chromatograph of the Cytb Gene, MCF-7    62 
3.18 ABI Chromatograph of the Cytb Gene, C12     62 
3.19 BSA (fraction V) Standard Curve      64 
3.20 Citrate Synthase Assay       65 
3.21 The Reduction of nicotinamide adenine dinucleotide (NADH) to NAD 66 
3.22 Essential Components of the Complex III Assay    68 
3.23 Schematic of Relative Enzyme Activities     70 
3.24 AAPH Treated Cells        72 
3.25 DPPH Treated Cells        73 
3.26 MCF-7 Cells in the 53rd Generation      73 
3.27 Population Growth Curve, AAPH and DPPH    74 
3.28 WST-1 Growth Curve, AAPH and DPPH     75 
3.29 Response to Free Radical Genertors      76 
3.30 DNA Isolated from Radical Study      76 
3.31 PCR Precipitate of the Cytb Gene      77 
3.32 PCR of the ND1 Gene       78 
3.33 PCR Precipitate of the COI Gene      78 
3.34 PCR Precipitate of the D-loop Gene      79 
3.35 AAPH Treated DNA        80 
3.36 DPPH Treated DNA        80 
3.37 Potential Transformation of MCF-7 Cells with AAPH   81 
iii 
 
4.1 OXPHOS Enzyme Activities in Relation to Function   88 
 
 
List of Tables 
 
2.1 PCR Primer Pairs        33 
 
3.1 Trypan Blue and WST-1 Estimates of PDT     54 
3.2 Genomic DNA Quantification      56 
3.3 Mitochondrial Mutation Baseline for MCF-7    58 
3.4 Summary of Mitochondrial Heteroplasmy     63 
3.5 Protein Yield from Mitochondria Extraction     64 
3.6 Citrate Synthase Enzyme Activity      65 
3.7 Complex I- NADH Dehydrogenase Enzyme Activity   66 
3.8 Complex II- Siccinate Dehydrogenase Enzyme Activity   67 
3.9 Complex III- Ubiquinl Cytochrome c Oxidoreductase Enzyme Activity 68 
3.10 Complex IV- Cytochrome c Oxidase Enzyme Activity   69 
3.11 Relationship Between Mitochondrial Heteroplasmy and PDT  71 
3.12 Genomic DNA Quantification      77 
 
List of Equations 
 
1.1 Energy Yield of the TCA Cycle      5 
1.2 Overall Energy Yield of Energy Conversion Pathways   6 
1.3 Complex I Reduction of NADH      7 
1.4 Complx II Reduction of Succinate      8 
1.5 Complex III Oxidation of UQH2      9 
1.6 Complex IV Oxidation of Cytochrome c     9 
1.7 Homolytic Fission of Hydrogen Peroxide     10 
1.8 Reduction of Free Iron       13 
1.9 Formation of Hydrogen Peroxide      13 
1.10 Formation of the Hydroxyl Radical      14 
1.11 Propagation of Lipid Peroxidation      14 
 
 
Chapter 1 - Introduction 
 1
CHAPTER 1 
 
INTRODUCTION 
_____________________________________________________________________ 
 
 
 
 
 
1.1 The Mitochondria        2 
 1.1.1  The Mitochondrion       2 
 1.1.2 The Mitochondrial Genome      2 
 
1.2 Energy Conversion Pathways      3 
 1.2.1 Glycolysis        3 
 1.2.2 The Tricarboxylic Acid Cycle     4 
 1.2.3 The Respiratory Chain      6 
  1.2.3.1  Complex I      7 
  1.2.3.2  Complex II      8 
  1.2.3.3  Complex III      8 
  1.2.3.4  Complex IV      9 
  1.2.3.5  ATP Synthase      10 
 
1.3 Reactive Oxygen Species       10 
 1.3.1 Lipid Peroxidation       12 
 1.3.2 Fenton Chemistry in Biological Systems    13 
 
1.4 Mitochondrial Mutation and Disease     15 
 1.4.1 Mitochondrial Mutation Load     16 
 1.4.2 Human Mitochondrial Mutation Rate    16 
 1.4.3 Mitochondrial DNA Copy Number     18 
 1.4.4 Mitochondrial Heteroplasmy      18 
1.4.5 Mitochondrial Hyper-mutagenesis in Some Cancer Cell Lines 19 
 
1.5 The MCF-7 Cell Line as a Model      20 
 
1.6 Thesis Aspirations        21 
  
 
 
 
 
 
 
 
 
 
 
Chapter 1 - Introduction 
 2
 
Figure 1.1. The Human Mitochondrion. 
Indicated are the inner cristae in which the 
OXPHOS enzymes are embedded. Figure 
taken from J. D. Ross is an electron 
micrograph approximately 30,000 x. 
1.1 Mitochondria 
 
1.1.1 The Mitochondrion 
 
Mitochondria consist of an outer membrane 
encasing an inner membrane of an 
undulating appearance, known as the inner 
cristae (Figure 1.1). This inner membrane 
hosts the protein complexes of oxidative 
phosphorylation (OXPHOS) (Ruiz-Pesini et 
al., 2000a; Shoubridge, 2001; Barrientos, 
2002). Oxidative phosphorylation requires 
the concerted effort of the mitochondrial 
and nuclear genomes to produce functional membrane protein complexes (Ruiz-Pesini 
et al., 2000b; Diez-Sanchez et al., 2003; Ballard and Whitlock, 2004).  
 
1.1.2 The Mitochondrial Genome 
 
The mitochondrial genome (Figure 1.2) consists of a circular, double stranded DNA 
molecule of 16,659 base pairs (Anderson et al., 1981; Wallace, 1999). It contains 37 
genes (2 encoding ribosomal RNAs, 22 encoding transfer RNAs, and 13 encoding 
polypeptides) partially encoding the enzymes of OXPHOS. The mitochondrion is also 
capable of independently replicating its own genome (Emmerson et al., 2001; Diaz et 
al., 2002; Chen et al., 2003). The majority of mammalian cells contain between 102 
and 104 copies of mtDNA (Wallace et al., 1999; Cavelier et al., 2000; DiMauro et al., 
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2000; Chen et al., 2003). The existence of so many copies of mtDNA is due to the 
mitochondrias main function of producing cellular energy. This occurs through three 
energy conversion pathways; glycolysis, the tri-carboxylic acid (TCA) cycle and 
OXPHOS. 
 
Figure 1.2. The Mitochondrial Genome. 
Figure taken from MITOMAP- a human 
mitochondrial genome database 
www.mitomap.org 
 
 
 
1.2 Energy Conversion Pathways 
 
1.2.1  Glycolysis 
 
Glycolysis is an anaerobic process that occurs in the cellular cytosol. The glycolytic 
pathway primarily involves the catabolic degradation of glucose and simple sugars. 
Phase 1 involves the phosphorylation of glucose and subsequent conversion of 
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glucose-6-phosphate to two molecules of glyceraldehyde-3-phosphate (G3P) through 
a series of steps, consuming two molecules of ATP in the process. Phase 2 of 
glycolysis converts the G3P through a series of steps into pyruvate yielding four 
molecules of ATP. This results in a net production of two molecules of ATP and two 
of pyruvate per molecule of glucose. Figure 1.3 provides a simplified overview of 
glycolysis. 
 
Figure 1.3. A simplified schematic of glycolysis in which a net gain of 2 ATP 
molecules are produced. Figure from the British Broadcasting Corporation 
www.bbc.co.uk. 
 
The production of pyruvic acid is in preparation for the next metabolic step- the TCA 
cycle.  
 
1.2.2 The Tricarboxylic Acid Cycle 
 
The TCA cycle utilises acetyl-CoA primarily produced from the conversion of 
pyuvate by pyruvate dehydrogenase. Carbon units enter the TCA cycle as acetyl-CoA 
and are expelled as carbon dioxide through a series of reactions. Figure 1.4 provides a 
simplified schematic of the changes in carbon units and concomitant loss of carbon 
dioxide experienced through the TCA cycle. 
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Figure 1.4. The Tricarboxylic Acid Cycle. Figure from the British 
Broadcasting Corporation www.bbc.co.uk. 
 
 
Energy is yielded from the TCA cycle in a variety of forms including adenosine tri-
phosphate (ATP), nicotinamide adenine dinucleotide (NADH) and membrane bound 
reduced flavin adenine dinucleotide (FADH2). These are summarized in Equation 1.1  
(Garrett and Grisham, 1999). Pi represents inorganic phosphate. 
 
Equation 1.1 
 
Acetyl-CoA + 3 NAD+ + [FAD] + ADP + Pi + 2 H2O  
   2 CO2 + 3 NADH + 3 H+ + [FADH2] + ATP + CoASH 
 
This thesis focuses on the next step in metabolism-oxidative phosphorylation. The 
stoichiometric relationship between the processes of glycolysis, the TCA cycle and 
OXPHOS is as follows in Equation 1.2: 
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Equation 1.2 
 
NADH + H+ + ½ O2 + 3 ADP + 3Pi  NAD+ + 3 ATP + 4 H2O 
[FADH2] + ½ O2 + 2 ADP + 2 Pi  [FAD] + 2 ATP + 3 H2O 
 
A maximum of thirty-four molecules of ATP is produced during the entire process of 
energy conversion, with three ATP molecules per NADH and two ATP molecules per 
FADH2 (Garrett and Grisham, 1999). This will be detailed in the following section. 
Mitochondria act as the powerhouse of a cell, supplying the bulk of the cellular 
energy request by means of the last step energy conversion step, OXPHOS (Wallace 
et al., 1999). This energy is stored via an electrochemical gradient (∆Ψm) created by 
active transport of protons across the inner mitochondrial membrane. Passive 
diffusion of protons through ATP synthase produces ATP  (Wallace et al., 1999; 
Barrientos, 2002; Smith, 2004). The first four complexes of OXPHOS are known as 
the respiratory chain. 
 
 
1.2.3 The Respiratory Chain 
 
 
 
The respiratory chain consists of four multimeric complexes (I-IV) (Figure 1.5) and 
two enzymes (ubiquinone and cytochrome c) that act as mobile electron carriers 
(Garrett and Grisham, 1999). This electron transfer from reducing equivalents creates 
a proton gradient across the inner membrane through a detailed system of 
chemiosmotic coupling (Garrett and Grisham, 1999; Barrientos, 2002).  
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The thirteen mtDNA translation products make up the subunits of four of the five 
complexes of OXPHOS (Complexes I, III, IV (respiratory chain) and ATP synthase, 
complex V) (Shoubridge, 2001; Jacobs, 2003).  
 
 
 
 
Figure 1.5. Complexes I-IV of the electron transport chain involved in oxidative phosphorylation. 
Figure taken from Homo sapiens draft oxidative phosphorylation GenomeNet 2004 
 
 
 
1.2.3.1  Complex I NADH-Coenzyme Q Reductase 
 
 
Complex I supplies ubiquinone to complex III through the electron acceptor, 
ferricyanide (Rustin et al., 1996; Barrientos, 2002). It achieves this by the oxidation of 
reduced NADH to NAD+ coupled with the reduction of flavin mononucleotide 
(FMN) (Equation 1.3, Garrett and Grisham, 1999).  
 
Equation 1.3 
NADH + [FMN] + H+ → [FMNH2] + NAD+ 
 
 
It is the most structurally complex of all the OXPHOS enzymes with at least 40 
subunits (Hofhaus et al., 1995; Barrientos, 2002). It has a molecular mass of 900 kDa 
Complex I            Complex II   Complex III  Complex IV 
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and is under dual (mitochondrial and nuclear) genetic control (Hofhaus et al., 1993; 
Hofhaus et al., 1995; Bourges et al., 2004).  
 
 
1.2.3.2  Complex II Succinate-Coenzyme Q Reductase 
 
Complex II is solely encoded by nDNA, producing four non-equivalent polypeptides 
(Garrett and Grisham, 1999; Barrientos, 2002). These subunits are associated with 
anchor proteins in the mitochondrial membrane. A flavin is covalently linked to a 70 
kDa peptide, known as the flavoprotein subunit (Fp) (Figure 4.2). Complex II is a 140 
kDa multimeric complex that catalyses the oxidation of succinate to fumarate, 
coupled with the reduction of ubiquinone (UQ) (Equation 1.4, Garrett and Grisham, 
1999). Complex II produces reduced ubiquinone (UQH2), the substrate of complex III 
but does not directly transport protons across the inner membrane. 
 
 
Equation 1.4 
Succinate→ Fumarate + 2H+  + 2e- 
UQ + 2 H+ + 2e- → UQH2 
 
 
1.2.3.3  Complex III- Coenzyme Q-Cytochrome c Reductase 
 
Complex III supplies cytochrome c (II) to complex IV. Complex III is a 496 kDa 
complex, which also facilitates the transport of protons across the inner membrane 
increasing ∆Ψm. This requires the oxidation of UQH2 yielding two electrons  which 
are supplied to cytochrome c (III) (Garrett and Grisham, 1999; Barrientos, 2002). The 
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reduction of cytochrome c (III) involves a complex redox pathway known as the Q 
cycle. Briefly, UQH2 diffuses into a complex III site termed Qp. A series of redox 
steps occur forming an intermediate product, semiquinone (UQ⋅-), at the Qp site. 
Semiquinone is converted to ubiquinone as electrons are again acquired from the 
oxidation of UQH2 at the Qp site. This results in the reduction of cytochrome c. The 
overall process for complex III is represented in Equation 1.5. 
 
Equation 1.5 
 
UQH2 + 2 H+in + 2 Cyt c (III) → 4 H+out + 2 Cyt c (II) + UQ 
 
 Reduced cytochrome c is the mobile electron carrier between complexes III and IV. 
 
1.2.3.4  Complex IV- Cytochrome c Oxidase 
 
Cytochrome c oxidase (complex IV) catalyses the transfer of electrons from 
cytochrome c (II) to molecular oxygen (DAurelio et al., 2001; Barrientos, 2002). It 
has thirteen subunits of mitochondrial and nuclear origin comprising a 204 kDa 
complex (Garrett and Grisham, 1999). The catalytic core contains three mtDNA 
encoded subunits. The reaction is represented in Equation 1.6 (Garrett and Grisham, 
1999). Protons are also actively transported across the membrane during complex IV 
activity. 
 
Equation 1.6    
4 Cyt c (Fe2+) + 4 H+  + O2 → 4 Cyt c (Fe3+) + 2 H2O 
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1.2.3.5  ATP Synthase 
 
 
ATP synthase (complex V) promotes the synthesis of ATP by the diffusion of protons 
through the Fo and F1 rotating components of the complex, spanning the 
mitochondrial membrane (Aggeler et al., 2002). It is the only OXPHOS complex that 
allows diffusion of protons into the inner membrane. (Garrett and Grisham, 1999; 
Barrientos, 2002; Aggeler et al., 2002; Smith, 2004). ATP hydrolysis (cleavage of 
hydrolytic bonds) is the primary energy source for the processes of biosynthesis and 
muscle contraction (Smith, 2004) creating a free energy change (∆Gû) of -31 kJ/mol. 
ATP is in fact, an energy carrier as close to a 40 kg turnover of ATP per day is 
experienced in the average human body, with only 50-70 mg of adenosine phosphates 
present at any given time (Smith, 2004). Any change in the capacity of OXPHOS in 
high energy demanding tissues may noticeably impair cellular function in terms of 
reduced cell proliferation.  
 
 
 
1.3 Reactive Oxygen Species 
 
 
 
In metabolism, reactive oxygen species (ROS) are formed by the reaction of 
superoxide with surrounding bio-molecules (Halliwell and Gutteridge, 1999). These 
can be proteins, other ROS, or nucleic acid. A typical formation of free radicals is the 
homolytic fission of hydrogen peroxide, producing two hydroxyl radicals (Equation 
1.7). This may occur in a biological system increasing hydroxyl radical concentration. 
 
Equation 1.7  
H2O2 →  2 ·OH 
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The hydroxyl radical can react with nitrogen bases in purines and pyrimidines in a 
biological system as follows in Figure 1.6; 
NH
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Figure 1.6. Nucleic acid damage mediated by the hydroxyl radical 
 
 
8-Hydroxyguanine (8-oxo-dG) is a common marker of DNA damage (Fujii et al., 
2002). A by-product of OXPHOS is the production of ROS in the form of superoxide. 
Superoxide is produced during metabolism in which leakage of electrons react with 
oxygen to form a reactive oxygen species. Superoxide reacts with local bio-molecules 
to produce a host of reactive species that can cause widespread damage. It is estimated 
that each mitochondrion may generate 107 radicals/day (Max, 1992). Additionally, 
due to the lack of stringent repair mechanism, it is proposed that mtDNA has a 
mutation rate of 5-10 times that of nuclear DNA due to ROS mediated damage and 
the absence of protective histone proteins (Brown et al., 1979; Croteau and Bohr, 
1997). 
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There is, however, a relationship between ROS, cell proliferation and growth-related 
signalling pathways (Arnold et al., 2001; Behrend et al., 2003). This gives ROS a 
positive role within a biological system, though much activity is counter production. 
Of particular relevance to cellular damage is the involvement of ROS in lipid 
peroxidation. Lipid accumulation is associated with a decrease in male fertility with 
age (Holstein et al., 2003), cellular transformation (Takabe et al., 2001) and apoptosis 
(Gieseg et al., 2000). 
 
Reactive oxygen species have been implicated in human male infertility, 
atherosclerosis, neuro-degenerative disease, diabetes and a host of diseases (Twigg et 
al., 1998; Aitken and Krausz, 2001; Gil-Guzman et al., 2001; Behrend et al., 2003; 
Wang et al., 2003; Moustafa et al., 2004; Sanocka and Kurpisz, 2004). Indeed, there 
are reports of high levels of ROS in 20-40% of infertile men (Aitken et al., 1997; Gil-
Guzman et al., 2001), though healthy sperm production and cellular function is 
dependant upon physiological levels of ROS (Zini et al., 1995; Aitken et al., 1997; 
Allen et al., 1997; de Lamirande et al., 1998; Richer and Ford, 2001; St John et al., 
2001; Sanocka and Kurpisz, 2004). It is yet unknown at what level ROS induce 
damage and what levels are necessary for healthy cellular function (Behrend et al., 
2003; Sanocka and Kurpisz, 2004).  
 
1.3.1 Lipid Peroxidation  
The plasma membrane is particularly susceptible to oxidative stress due to being 
enriched with polyunsaturated fatty acids (PUFAs) that are essential for membrane 
fluidity, which is required for membrane vesicle fusion (Aitken and Krausz, 2001; 
Khosrowbeygi et al., 2004) and functional ability (Sanocka and Kurpisz, 2004). Lipid 
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inclusions and peroxidation have been implicated in disease (Folgero et al., 1993; 
Aitken and Krausz, 2001; Miller et al., 2001). 
 
Oxidative stress induces peroxidation of PUFAs in the plasma membrane, with the 
potential knock-on effect of DNA damage of both mitochondrial and nuclear 
genomes (Aitken and Krausz, 2001; Takabe et al., 2001). Mitochondrial DNA 
damage that results in less efficient metabolism may encourage greater superoxide 
production along with subsequent ROS reactions (Diaz et al., 2002). 
 
1.3.2 Fenton Chemistry in Biological Systems 
A mediator of the formation of highly damaging ROS in a biological system is free 
iron. Though generally tightly chelated, free iron is present at low levels in a 
biological system. Fenton chemistry is the reaction of ROS with free iron. In the 
presence of Fe3+, hydroperoxides can undergo a reaction yielding Fe2+ by 
translocation of a proton. This is described in Equation 1.8. 
 
Equation 1.8 ROOH + Fe3+ →RO·2 + Fe2+ + H+ 
 
         
This yields the peroxyl radical (HO·2) capable of undergoing the following reaction.  
Equation 1.9  
-CH2- + HO·2 → -·CH- + H2O2 
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This gives rise to hydrogen peroxide (H2O2). Hydrogen peroxide can also react with 
Fe2+ giving rise to the hydroxyl radical (HO·), a potent mediator of bio-molecular 
damage. 
 
Equation 1.10 
 
 
H2O2 + Fe2+ →HO· + OH- + Fe3+ 
                      
In the present research, AAPH (peroxyl radical generator) was selected to test the 
potential for mitochondrial DNA damage in MCF-7 cells. Azo initiators such as 
AAPH also produce superoxide, which rapidly converts to the protonated form and 
reacts with lipid hydroperoxides forming hydrogen peroxide, a key ROS in biological 
systems (Equation 1.10, Halliwell and Gutteridge, 1999). Superoxide releases iron 
from iron-sulphur centred proteins that can generate carbon centred radicals, which 
initiate lipid peroxidation (Murphy et al., 2003). This can result in a chain reaction 
(propagation) of lipid peroxidation shown in Equation 1.11. (Simandan et al., 1998). 
 
Equation 1.11  
 
 
-CHO·2 +  -CH2 → -CHO2H + -C ·H 
 
 
Fenton chemistry is responsible for the production of many reactive oxygen species in 
a biological system. Understanding the role of hydrogen peroxide as a pro-oxidant 
species is important in the present research as H2O2 can produce a host of other 
reactive oxygen species in a biological system, with potential for nucleic acid 
modification. Figure 1.7 summarizes the key pathways in the neutralization of 
hydrogen peroxide, working to counter bio-molecular damage. 
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1.4 Mitochondrial DNA Mutation and Disease 
 
Mitochondria play a key role in providing energy for cell proliferation and sustaining 
cellular activity (Snustad and Simmons, 1997; Ruiz-Pesini et al., 1998; Rossignol et 
al., 2000; Ruiz-Pesini et al., 2000a). Thus, mitochondrial heteroplasmy or mutation 
may influence ROS production (in the form of increase superoxide production), and 
induce disease states in organs that are dependant on consistent energy production and 
suffer when energy production declines (Halliwell and Gutteridge, 1999; Chomyn et 
al., 2000; DiMauro and Schon, 2001; Yasukawa et al., 2001; Kirino et al., 2005). The 
presence of mutant cells in laboratory cultures may be determined by slow cell 
proliferation and substantial cell death. Biochemical communication between 
O2       O2-·              H2O2            ·OH         H2O 
e- e- + 2H+ e- + H+ e- + H+ 
Superoxide Hydrogen 
peroxide 
Hydroxyl
radical 
Superoxide
dismutase Catalase
GSH  GSSG 
NADPH NADP- 
Glutathione reductase 
Glucose-6-phosphate dehydrogenase 
Glutathione peroxidase
Key Pathways of Antioxidants Relating to Hydrogen Peroxide Neutralisation
Figure 1.7. Summary of the major antioxidant pathways relating to hydrogen 
peroxide. 
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mitochondria and the cell nucleus has been associated with a degree of control of the 
signalling involved in apoptosis, cell proliferation and differentiation of normal and 
malignant cells (Felty and Roy, 2005). 
 
 
1.4.1 Mitochondrial Mutation Load 
 
The mutant load of mtDNA in tissues can be influenced in two ways. Firstly, there is 
an ever-present background of ROS production and tissue toxins. Secondly, mtDNA 
deletions producing a smaller genome tend to replicate faster, accumulating with age 
(Cummins et al., 1994; Diaz et al., 2002). This can result in decreased metabolic 
activity and increased ROS production causing more damage to both DNA and 
proteins (Diaz et al., 2002).  
 
1.4.2 Human Mitochondrial Mutation Rate 
 
Mitochondrial DNA mutates faster than nuclear DNA due to localized ROS 
production (Brown et al., 1979; Wallace et al., 1999; DiMauro and Andreu, 2000). 
Thus, tissues with a higher metabolic demand, in the form of increased ATP 
consumption, experience higher levels of mtDNA deletion (Cortopassi et al., 1992). 
Estimates of the human mitochondrial mutation rate vary greatly and can span up to 
two orders of magnitude (Siguroardottir et al., 2000). In the hypervariable region I 
(mt16024-16383) and hypervariable region II (mt57-371) a value of 0.0043 mutations 
per generation was estimated from mutational studies of 272 individuals 
(Siguroardottir et al., 2000). The higher mutation rate of mtDNA results in 
mitochondrial haplogroups that differ between populations (Wallace et al., 1999). It is 
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possible that haplogroups exist within a cell culture that contains sub-populations such 
as MCF-7.  
 
Mitochondrial DNA mutations are responsible for a host of diseases that arise due to 
impaired energy output. These include mitochondrial myopathies, encephalopathy, 
lactic acidosis, stroke-like episode (MELAS) (Klug and Cummings, 1997; Chomyn et 
al., 2000; DiMauro and Andreu, 2000; Kirino et al., 2004; Kirino et al., 2005), 
myoclonus epilepsy associated with ragged red fibres (MERRF) (King and Attardi, 
1989; Klug and Cummings, 1997; Yasukawa et al., 2001), Lebers hereditary optic 
neuropathy (LHON), progressive external ophthalmoplegia (PEO) and a host of others 
(Hofhaus et al., 1996; DiMauro and Schon, 2001; Kirino et al., 2005). These include 
the influence of mitochondrial haplotypes (Cummins et al., 1994; Folgero et al., 1993; 
Ruiz-Pesini et al., 2000), mutations or deletions and mitochondrial heteroplasmy 
(Cummins et al., 1994; Wallace et al., 1999; DiMauro and Andreu, 2000; Quintana-
Murci et al., 2001; Diaz et al., 2002; Bai et al., 2004).  
 
Mitochondrial DNA mutations exist in two broad categories; mutations that affect 
mitochondrial protein synthesis (single nucleotide deletions or substitutions involving 
rRNA and tRNA genes) (DiMauro and Schon, 2001; Suzuki et al, 2002; Kirino et al., 
2004; MITOMAP, 2005) and those that are present in protein coding genes (DiMauro 
and Andreu, 2000; DiMauro and Schon, 2001; MITOMAP, 2005). Expectedly, cells 
harbouring pathological tRNA mutation within the mtDNA exhibit decreased 
OXPHOS complex activity, lowered oxygen consumption, and reduced cellular 
growth rates (Jacobs, 2003). Currently ninety pathogenic mitochondrial tRNA 
mutations are known (MITOMAP, 2005). The outcome of many of these mutations is 
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impaired energy output due to lowered efficiency of the OXPHOS enzymes, most 
evident in tissues requiring a large energy supply (DiMauro and Andreu, 2000) such 
as muscle tissue, spermatozoa and cancer cells. 
 
1.4.3 Mitochondrial DNA Copy Number 
 
The copy number of mitochondria DNA per cell is dependant on cellular energetic 
demand (May-Panloup et al., 2003). The majority of mammalian cells contain 102 to 
104 copies of mtDNA. Some mitochondria contain up to 11 copies of mtDNA, others 
are devoid of mtDNA (Cavelier et al., 2000). At the molecular level, this reduction is 
due to the down regulation of the mitochondrial transcription factor A (tfam) 
controlling mitochondrial DNA copy number (Larsson et al., 1997; Rantanen et al., 
2001). In the present research, citrate synthase activity will be monitored in cell clone 
cultures as an indicator of mitochondrial DNA copy number. 
 
1.4.4 Mitochondrial Heteroplasmy 
 
There exists a cell-to-cell variable load of mutant to wild-type mitochondrial DNA. 
(Wallace et al., 1999; DiMauro and Andreu, 2000; Quintana-Murci et al., 2001). 
Heteroplasmy is a state in which mutant and wild type mitochondrial DNA exists 
within a tissue or even a single cell. The situation in which cells or tissues have 
identical mitochondrial DNA is known as homoplasmy (DiMauro and Andreu, 2000). 
 
The mutational state of heteroplasmy tends to drift towards homoplasmy over time. 
This process is known as replicative segregation (Wallace, 1986; Wallace et al., 1999; 
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DAurelio et al., 2001; Battersby et al., 2003). As cells divide it is by chance that one 
daughter cell may receive mutant mitochondrial DNA. Over time, the percentage of 
mutant or wild type mtDNA will drift toward a pure mutant, or a homoplasmic state 
(Wallace, 1986). For this reason, many mitochondrial myopathies will not be evident 
until later in life due to mutant DNA accumulation. Increase of mutant mtDNA is met 
with a concomitant decline in cellular energy production (Wallace et al., 1999).  
 
The proportions of mutant and wild type mitochondrial genomes can vary between 
different tissue types (Cavelier et al., 2000) and the same tissue of an individual 
(Grzybowski, 2000; Quintana-Murci et al., 2001; Chen et al., 2003). Further, a given 
cell can exist in a heteroplasmic state (Grzybowski, 2000). The variation of 
mitochondrial deletion in different people of similar age appears to be less than the 
variation amongst different tissues of an individual (Cortopassi et al., 1992). 
Additionally, a state of heteroplasmic deletion can be present within the genome that 
is difficult to determine by conventional PCR and sequencing for single deletions, as 
the wild type sequence will still appear, but at a reduced level of the base in question 
(Holt et al., 1989). 
 
1.4.5 Mitochondrial Hyper-mutagenesis in Some Cancer Cell Lines 
 
A high frequency of homoplasmic point mutation is detected in a range of human 
tumours. The rates range from 70% in colon tumour cell lines to 15% in prostate 
(Chen et al., 2003). At the very least, a significant subset of human tumours 
experience frequent mutational events within the mtDNA. This is proposed to occur 
as the cell shifts from a benign epithelial cell to a malignant cell, of high oxygen 
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consumption particularly in prostate tumours (Costello and Franklin, 2000). This 
directly relates to OXPHOS, as mitochondria are the primary source of ROS, 
heightened with increased oxygen consumption. Chen et al. (2003) found a process of 
mitochondrial hyper-mutagenesis in place, potentially mediated by increased 
oxidative stress in three prostate tumour cell lines (Chen et al., 2003). This was 
proposed due to the discovery of local homoplasmy of mutation, and linkage of 
multiple mitochondrial mutations occurring along the course of tumour progression 
(Chen et al., 2003). It is as yet unknown whether the MCF-7 cell line has, or can be 
induced to high oxygen consumption. Moreover, it is an important aspect of using 
cancer cell line models in studying mitochondrial genetics, whether a process of 
hyper-mutagenesis is active.  
 
1.5 The MCF-7 Cell Line as a Model 
 
A cell line model can be employed to elucidate the influence of genetic factors on 
cellular proliferation and morphological changes, both of which may indicate DNA 
modification. Consistent treatment of a cell line during study is paramount to obtain 
meaningful results. Cell line models are also useful for in organello assessment of 
mitochondrial protein synthesis (Gaines and Attardi, 1984; Micol et al., 1997) and 
OXPHOS function (Barrientos, 2002). The MCF-7 cell line contains sub-populations 
(Devarajan et al., 2002; Zou and Matsumura, 2003), useful for the isolation of single 
cell clones with the potential for genetic variation. MCF-7 is a well-characterized cell 
line (Sutherland et al., 1983; Devarajan et al., 2002; Zou and Matsumura, 2003; 
Lacroix and Leclercq, 2004; Zivadinovic et al., 2004) which has been used in 
studying environmental factors (Zou and Matsumura, 2003), chemotherapeutic drugs 
Chapter 1 - Introduction 
 21
(Sutherland et al., 1983; Taylor et al., 1983), drug resistance (Devarjan et al., 2002), 
and reactive oxygen species (Hand and Craven, 2003).  
 
1.6 Thesis Aspirations 
 
The MCF-7 cell line will be used to assess the effect of free radical generators on 
mitochondrial mutation, OXPHOS activity and rate of cell proliferation. 
Morphological changes under the influence of free radical generators will be 
determined. In order to achieve the research goals, cell cultures with a homogenous 
genetic background will be established by isolating single cell clones from an MCF-7 
stock culture. Mutations in the mitochondrial genome will be analysed by sequencing 
of selected genes and the activities of the OXPHOS enzymes will be assayed by 
standard biochemical technique. Further, mutation rates of the MCF-7 stock culture 
will be assessed after a known number of cell generations.  
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2.1 Materials 
 
All materials were of molecular biology grade. Chemical abbreviations are listed in 
Appendix A. For a comprehensive list of suppliers, refer to Appendix C. Distilled, 
deionised water (ddH2O) was prepared by ultra filtration with a Barnstead NANO 
Pure Ultrapure water system (IO, USA). Chemical solutions and ddH2O were 
autoclaved before use. 
 
2.2 Methodology 
 
2.2.1 Cell Culture 
 
2.2.1.1  MCF-7 Cell Line  
 
MCF-7 is a cell line derived from mammary epithelial adenocarcinoma from a 69-
year-old Caucasian woman (American type culture collection (ATCC) cell line HTB-
22). It was derived from a pleural effusion metastatic site. Its morphology is 
polygonal and adherent and has been well characterized (ATCC; Mambo et al., 2002; 
Zou and Matsumura, 2003). Widely used by research laboratories, it is suitable as a 
cell line model (Sutherland, 1983; Devarajan, 2002; Lacroix and Leclercq, 2004).  
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2.2.1.2  Cell Culture Conditions 
 
Aseptic techniques were strongly adhered to as outlined by Freshney (Freshney, 
2001). Cultures were worked with in a vertical laminar flow hood (Figure 2.1 A) 
(Clyde-Apac BH2000 series) and the cultures were maintained at 37ûC in a CO2 
incubator (Sanyo MCO-20AIC) at 5% CO2. All reagents for cell culture were pre-
warmed to 37ûC before use. Cell cultures were grown to 80-95% confluence before 
sub-culturing or freezing. Cells morphology was visualised with an inverted 
microscope (Figure 2.1 B) (Leitz Diavert, Welzler, Germany) and photographed with 
a hand-held Sony Cybershot 5.1 Megapixel camera. 
 
  
Figure 2.2. A, The vertical laminar flow hood, B, Visualizing cell cultures with an 
inverted microscope 
 
2.2.1.3  Preparation of Cell Culture Medium 
 
All cell culture reagents were obtained from Gibco, Invitrogen, New Zealand and 
stored as recommended by the manufacturer. Dulbeccos modified eagles medium 
(DMEM, 0.1 µm filtered) contained 4500 mg/L D-glucose, 584 mg/L L-glutamine, 
110 mg/L sodium pyruvate and 4 mg/L pyridoxine hydrochloride, alongside standard 
DMEM reagents (Gibco, Invitrogen). The medium was supplemented with foetal 
A B
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bovine sera (FBS, 9.85 %, Invitrogen, New Zealand source), and 49 units/ml 
penicillin-streptomycin (Gibco, Invitrogen). 
 
2.2.1.4  Initial Cell Seeding 
 
A 1.0 ml aliquot of MCF-7 cells (6.9 x 106) obtained from Dr Drusilla Mason (School 
of Biological Sciences, University of Canterbury, New Zealand) were seeded into a 
T-75 flask. Growth medium (GM, 19.0 ml) was dripped into the flask over two 
minutes to reduce osmotic shock. The cells were incubated for four hours (to 
adherence). The culture medium was refreshed to remove dimethyl sulfoxide 
(DMSO) from culture freezing.  
 
2.2.1.5  Harvesting and Subculturing of MCF-7 Cells 
 
To harvest the cells the culture medium was removed by aspiration and 2.0 ml 
trypsin/EDTA 0.25%/1 M was applied to the monolayer to detach cells. The culture 
was incubated for 2-5 minutes at 37ûC until all cells had detached from the surface. 
Eight ml of GM was added to dilute the trypsin and a cell count was taken. 
 
2.2.1.6  Performing a Cell Count 
 
Cultures were thoroughly mixed prior to an aliquot being removed for cell counting 
or seeding. For cell counting, a 100 µl aliquot was removed and diluted with 100 µl 
trypan blue (Gibco, Invitrogen, New Zealand) cellular viability dye. Trypan blue will 
stain all dead cells, while living cells will actively exclude the dye (Gibco, Invitrogen, 
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New Zealand). From the dye suspension 3 µl was taken for cell counting. A Makler 
counting chamber (Sefi-medical instruments) with a 0.01 mm2 x 10 µm grid was used 
to determine the cell count. The cell count was adjusted for a dilution factor of two to 
correct for the addition of the dye. Percent viability was calculated by dividing viable 
cells by the total number of cells counted. Unless otherwise stated the percentage 
viability was above 90% (excluding plateau phase of population growth studies). 
 
2.2.1.7  Cell Culture Cryopreservation 
 
Aliquots (1.0 ml) of the cell culture suspension were centrifuged (Eppendorf 5417R) 
at 90 x g for 8 minutes. The supernatant was aspirated and the pellet washed with 1 x 
phosphate buffered saline (PBS, 0.26 M Na2HPO4, 0.09 M KH2PO4, 0.39 M NaCl), 
pH 7.4. The washed pellet was re-suspended in 1.0 ml 10% DMSO and transferred to 
cryotubes (Nunc-Nalgene). The cryotubes were slowly cooled in isopropanol for 2 
minutes and stored in a -80ûC chest freezer (GFL).  
 
2.2.1.8  Isolation of Single Cell Clones  
 
Conditioning medium was prepared from an equal volume of fresh GM and GM from 
exponentially growing cell cultures. Briefly, GM from exponentially growing culture 
was centrifuged at 53 x g (Eppendorf  5810R) to remove floating cells and cell debris. 
The supernatant was used to make up conditioning medium. For single clone isolation, 
MCF-7 mammary epithelial cells (second passage) seeded at 7.6 x 106 cells/ml were 
grown to 90% confluence in 19.0 ml GM in a T-75 flask. The culture medium was 
aspirated and 2.0 ml of trypsin/EDTA 0.25%/1 M (Gibco, Invitrogen, New Zealand) 
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was applied to the monolayer and incubated at 37ûC for 3-4 minutes or until cells had 
detached. Eight ml of conditioned GM was added to dilute the trypsin/EDTA and a 
cell count was performed with the resulting cell suspension. This was determined to 
be 1.08 x 106 cells/ml. Based on the cell count, a serial dilution was performed until 
the cell concentration was 10.77 cells/ml. Aliquots of 65 µl of cell suspension were 
seeded into each well of a Nunc 96 well plate, giving an average count of 0.7 
cell/well. The single cell wells were identified under a microscope and recorded. 
Wells with more than one cell were discarded. Conditioning medium was refreshed 
regularly until single cell clones had formed populations, after which standard growth 
media was introduced. Single cell clone cultures were established in T-75 flasks with 
GM. 
 
2.2.1.9  WST-1 and Trypan Blue Cell Estimates 
 
Trypan blue and the WST-1 cell proliferation assay are two methods for estimating 
cell population growth. The trypan blue cell count was performed by seeding 2 x 103 
cells/well in a 12 well plate (3.5 cm2) and performing cell counts (Section 2.2.1.6) at 
regular intervals.  
 
The WST-1 (4-[3-(4-Iodophenyl)-2-(4-nitorphenyl)-2H-5-tetrazolio]-1,3-benzene 
disulfonate) assay functions by the cleavage of a tetrazolium salt to a formazan 
product (Figure 2.2). An absorbance shift occurs due to a colorimetric change by the 
reduction of tetrazolium salts caused by cellular membrane enzymes. A WST-1 
calibration plot was formed by seeding wells with a know concentration of cells and 
measuring the absorbance at 450 nm with 690 nm as a reference wavelength. A 
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calibration curve was constructed from these measurements. Subsequent estimates of 
cell concentration could be determined by taking the average absorbance and 
calculating the corresponding cell count from the calibration curve. Culture medium 
was aspirated from wells to be assayed and replaced with 100 µl of phenol red free 
GM, supplemented with heat inactivated FBS. To the maintenance medium, 10 µl of 
WST-1 reagent was added and the culture was incubated for 4 hours. The plate was 
shaken prior to measurements being taken. Each time-point represents the mean (+ 
SE) of the number of cells from eight separate wells.  
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 Figure 2.2. WST-1 reagent. The WST-1 assay functions by the cleavage of the tetrazolium salt to a 
formazan product.  
 
 
2.2.1.10  Check for Bacterial Contamination 
 
All cultures were checked for bacterial contamination immediately before population 
growth studies and mitochondria isolation. Aliquots (1.0 ml) from cultures were 
seeded into 12 well plates (three wells per culture), and incubated for five days with 
antibiotic free GM.  
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2.2.2    DNA Analysis 
 
2.2.2.1  MCF-7 Cell Genomic DNA Extraction 
 
Cells were grown to a minimum of 85% confluence in T-75 or T-25 flasks in all 
instances. The growth medium was aspirated and 2.0 ml or 1.0 ml, respectively, of 
trypsin/EDTA 0.25%/1 M (Gibco, Invitrogen, New Zealand) was added. Cells were 
monitored using an inverted microscope until all cells had lifted from the well surface. 
The cell suspension was transferred to 1.5 ml microfuge tubes and centrifuged at 86 x 
g, room temperature, for eight minutes. The medium was aspirated and cell the pellet 
was washed with PBS and centrifuged as before. The PBS was aspirated and the cell 
pellet was treated with extraction buffer (900 µl; 0.1 M Tris HCl, 0.1 M NaCl, 20 mM 
EDTA (pH8)) and lysis mix (100 µl; 100 µg/ml proteinase K, 10 mM DTT, 1% SDS). 
Extractions were mixed thoroughly and incubated in a waterbath at 50ûC overnight. 
One volume of Tris-EDTA pH8 (TE8) saturated phenol was added to the cell solution. 
This was mixed thoroughly and centrifuged at 15,300 x g, for five minutes at ambient 
temperature. The aqueous phase was transferred to a new tube and the original tube 
was back-extracted with an equivalent volume of TE8. The two aqueous phases were 
combined and treated with equal volumes of phenol and chloroform 
(chloroform:isoamyl alcohol/24:1). The extraction was thoroughly mixed for five 
minutes and centrifuged as above. The aqueous phase was transferred to a new tube 
and one volume of chloroform was added. The extraction was centrifuged as above. 
The aqueous phase was transferred to a new tube and the DNA was precipitated with 
0.1 volume 3M NaOAc (pH 7.0) and two volumes of 100% cold ethanol. The 
resulting solution containing visible white strands of DNA was stored in the freezer (-
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20ûC) overnight. The DNA was pelleted at 15,300 x g for 20 minutes at 4ûC. The 
supernatant was aspirated and the DNA was washed with 70% cold ethanol. The 
DNA was re-suspended in TE8. 
 
2.2.2.2  Visualization of Isolated Genomic DNA 
 
Successful DNA extraction was confirmed by electrophoresis on a 1% (w/v) agarose 
(Sigma) gel prepared with 1 x TAE (Tris-acetate/EDTA 0.04 M/0.001 M, pH8). DNA 
(1 µl) with 1 x orange G loading buffer (30% glycerol, 0.35% orange G) was loaded 
into the gel and run at 80V (5V/cm) for 25 minutes. Gels were stained with ethidium 
bromide solution (0.5 µg/ml) for 15 minutes, with agitation, and visualized on an 
ultra-violet (UV) transilluminator at 300 nm. 
  
2.2.2.3  Genomic DNA Quantification 
 
DNA was quantified by determining the absorbance of 5 µl genomic DNA in 495 µl 
ddH2O at 260 nm and 280 nm. DNA concentration was calculated from the 
absorbance at 260 nm (one optical density (OD) unit at 260 nm is equivalent to 50 µg 
dsDNA/ml). The concentration of DNA was calculated with the following equation. 
 
DNA concentration (µg/µl) =  OD260 x 102 x 50 µg/ml   
        
          1000 
 
DNA was also quantified visually by a spotting technique. Quantities of λ DNA (0.3, 
0.1, 0.08, 0.06, 0.04 and 0.01 µg/µl) were spotted on a 1 % agarose gel as a 
concentration standard. Aliquots of 1 µl of each single clone isolated DNA and the 
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MCF-7 stock were spotted beside the marker. These were allowed to dry, stained in 
ethidium bromide, and visualised as above. The concentration of MCF-7 stock DNA 
and clone DNA were estimated by comparison to the λ DNA standards. 
 
2.2.2.4  Polymerase Chain Reaction (PCR) 
 
PCR reactions were performed in a 25 µl reaction volume and contained 1 x PCR 
buffer, 2 mM dNTP mix (dATP, dGTP, dCTP, dTTP) (Eppendorf), 2 mM MgCl2, 0.5 
units Taq DNA polymerase (Roche), 8 mM of forward and reverse primer (Hermann-
GbR) 
 
PCR was performed on a Perkin-Elmer DNA thermal-cycler 480 as follows:  
    80ûC  2 min (DNA added) 
    94ûC  2 min 
    94ûC  30 seconds 
    56-59ûC 30 seconds 30 x 
    72ûC  1 minute 
    72ûC  5 minutes 
    4ûC  SOAK 
 
The annealing temperature varied depending on the primer pair used (Table 2.1).
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2.2.2.4.1  Design of PCR Primers  
 
PCR primers were obtained from Hermann GbR (Bio-Strategy Distribution Ltd). 
Primers were designed using the Primer3 design software. Additional primers were 
designed with T7 and T3 tags for fluorescent tag binding in preparation for Licor 
DNA sequencing (Table 2.1). Primer pairs were designed to have complementary Tm 
values and an approximate 50% GC content. Tm values were supplied by Primer 3. 
 
2.2.2.4.2 Ethanol Precipitation of PCR Products 
 
PCR product was purified by ethanol precipitation. One volume of 4 M ammonium 
acetate (NH4OAc) and two volumes of isopropanol were added to 20 µl of PCR 
product. The solution was mixed by gentle inversion and incubated at room 
temperature for 20 minutes. The solution was centrifuged at 15,300 x g at room 
temperature for 20 minutes. The supernatant was removed and the pellet was washed 
with 70 % ethanol. The tube was centrifuged as before and the supernatant removed. 
Washing was repeated with 100% ethanol. The residual alcohol was removed with a 
finely drawn glass pipette and evaporated at ambient temperature before being re-
suspended in 10 µl TE8. Purified products (1 µl) were confirmed by electrophoresis 
and visualized as above. 
 
2.2.2.5  DNA Sequencing 
 
Mitochondrial DNA sequencing was achieve by employing Licor fluorescent DNA 
sequencing, and ABI Big Dye® Terminator sequencing version 3.1. 
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2.2.2.5.1 DNA Sequencing with Licor 4000L DNA Sequencer 
 
Thermosequenase reactions were performed using fluorescent primers (T7 forward, 
T3 reverse, Table 1) and a 1% mix of dideoxy termination nucleoside triphosphate 
bases (ddNTPs). A single reaction contained the following: 
   DNA + H2O  5.75 µl 
   Reaction buffer 1.0 µl 
   Fluorescent primer 1.0 µl (1 picomol) 
   Thermosequenase 1.0 µl 
 
   Volume  8.75 µl 
 
 
The mix was added to tubes containing 1.0 µl of each ddNTP, A, G, C, or T 
respectively. For this reaction A, G, C, T sequencing is performed separately. 
Forward and reverse priming reactions were also performed separately. The thermal 
sequencing reaction was performed using an Eppendorf Mastercycler® gradient as 
follows: 
   95ûC  5 min 
   95ûC  30 seconds 
   50ûC  15 seconds      29 x 
   70ûC  1 minute 
   95ûC  30 seconds 
   72ûC  1 minute        
   4ûC  SOAK 
    
Following thermal cycle amplification, 2.0 µl of stop buffer (bromophenol blue/ 
xylene cyanol, 1%, USB) was added. Samples were denatured at 95ûC for 5 minutes 
and chilled on ice immediately before electrophoresis and were loaded into a 6% 
polyacrylimide gel perforations made by a 0.25 mm shark tooth comb. A tank 
containing 1 x TBE (Tris-borate/EDTA) was used as a buffer. Samples were run at 
9 x 
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2250 V, 68.8 W, 30.6 mA for up to 12 hours. Image analysis was performed with 
Base ImageR software and sequences were assembled with Clustal X software v 1.7. 
A 6% polyacrylimide gel was prepared at a cross-linking ratio of 19:1; 190 g 
acrylimide to 10 g N,N-methylene-bis-acrylimide in a 40% (w/v) solution (Biorad). 
This consisted of 29.4 g urea, 7.0 ml 10 x Tris-borate/EDTA (TBE, pH 8), 5.6 ml 
long ranger polyacrylamide (19:1), made up to 70 ml with ddH2O. The mixture was 
gently heated until urea had dissolved. Immediately before pouring, 440 µl 10% APS 
(ammonium persulphate, Roche) and 35 µl TEMED (N, N, N', N'-Tetramethyl-
etheylenediamine, Sigma) was thoroughly mixed through the gel solution. The gel 
was immediately poured between two glass plates with a 0.25 mm spacer. This was 
allowed to polymerize at room temperature for two hours. 
 
2.2.2.5.2 DNA sequencing with ABI Prism version 3.1 
 
The majority of sequencing was performed using a BigDye®Terminator v 3.1 cycle 
sequencing kit. This technique utilises fluorescent dideoxy nucleoside triphosphates 
(dNTPs) which are inserted into the sequence as varying loci when the sequencing 
reaction is performed. The reaction conditions were: 
 
   96ûC  10 seconds 
   50ûC  10 seconds     24 x 
   60ûC  1 minute 
   15ûC  SOAK 
 
Samples are read at high voltage with an ABI 3100 genetic analyzer (Applied 
Biosciences). Sequences were visualized and aligned using the Bioedit software v 
7.0.4. 
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2.2.3 Oxidative Phosphorylation 
 
2.2.3.1  Isolation of Intact Mitochondria by Differential Centrifugation 
 
Exponentially growing MCF-7 cells were trypsinized and collected by centrifugation 
at 86 x g for eight minutes at room temperature. The resulting pellet was washed with 
1 x PBS (pH 7.4) and centrifuged as above. The cells were incubated for seven 
minutes at 4ûC with 400 µl 2 mg/ml digitonin, 600 µl of 0.1 M sucrose and 400 µl of 
1x PBS. The cells were then homogenized with a hand held grinder and centrifuged at 
2000 x g for five minutes at 4ûC to pellet the nucleus and unbroken cells (Sottocasa et 
al., 1967; Gaines and Attardi, 1984). The digitonin treatment was repeated to ensure 
complete lysis of the cells. The combined supernatant was layered on top of a two-
step gradient consisting of 400 µl 0.3M sucrose, 400 µl 1 x PBS (pH 7.4), 400 µl of 1 
mg/ml BSA (bovine serum albumin) fraction V (Boehringer, Germany) and 200 µl 
mineral oil chilled to 4ûC. The layered supernatant was centrifuged at 3000 x g for 40 
minutes. After centrifugation, a dark brown pellet with a top white fluffy layer was 
observed. The upper supernatant was discarded. The lower mitochondrial rich 
fraction should be free of contaminating cytosolic lactic dehydrogenase. The final 
supernatant was transferred into 1.5 ml tubes and spun at 19,000 x g for 40 minutes. 
The pellet was re-suspended in 0.6M sucrose and 20 mM HEPES (Sottocasa et al., 
1967; Diekert et al., 2001). The suspensions were stored at -80ûC (Tryoen-Toth et al., 
2003) for no longer than three weeks before assay. When required, the sample was 
thawed on ice and centrifuged at 19,000 x g for 40 minutes. The pellet was re-
suspended in hypotonic media consisting of 25 mM KH2PO4 and 5 mM  MgCl2 and 
freeze-thawed (Ruiz-Pesini et al, 1998) five times. This was accompanied with 5 x 1 
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minute bursts of sonication on a soniclear bath sonicator. The chilled mitochondrial 
homogenate was used for enzyme analysis. 
 
2.2.3.2  Protein Determination  
 
Protein content of the mitochondrial fractions was determined by the method of 
Bradford (Bradford, 1976). This was achieved using the BioRad protein assay 
(BioRad protocols) with a BSA standard. Briefly, assay reagent was diluted with four 
volumes of ddH2O and mixed thoroughly. To 980 µl dilute reagent, 20µl of protein 
sample was added, mixed, and the sample read at 595 nm. A standard curve was 
constructed using BSA at concentrations 50, 75, 100, 125, 150, 250, 500, 1000, 1500 
and 2000 µg/ml. The protein content of the unknown mitochondrial fraction was 
determined from this standard curve. 
 
2.2.3.3  Analysis of Oxidative Phosphorylation Enzymes 
 
Kinetic analysis of all the complexes of OXPHOS was performed in triplicate in 1.0 
ml glass cuvettes on a Shimandzu UV-160 1PC UV visible spectrophotometer at 
room temperature. Samples were kept at -80ûC in storage or 4ûC immediately before 
assay 
2.2.3.3.1 Citrate Synthase 
 
Citrate syntase activity was monitored spectrophotometrically by the formation of the 
mercaptide ion upon cleavage of DTNB (5,5-dithiobis-(2-nitrobenzoate)) (Srere, 
1960). This was indicative of mitochondrial copy number per cell (Ruiz-Pesini et al., 
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1998). Reagents were prepared as follows. DNTB, 1 mM, was prepared by dissolving 
3.9 mg of DNTB (free acid) in 10.0 ml of 1 M Tris-HCl, pH 8.1. Acetyl-CoA, 10 mM, 
was prepared by dissolving 10 mg of Acetyl-CoA in ddH2O. Oxaloacetate, 10 mM, 
was prepared by dissolving 1.32 mg oxaloacetate in 1 ml of Tris-HCl buffer (freshly 
prepared). The assay reagents were DTNB, 0.1 ml; acetyl CoA, 0.03 ml; 10 µg 
enzyme homogenate, 0.77 ml ddH2O (Srere, 1960). Absorption was followed at 412 
nm for 3 minutes to measure possible acetyl-CoA deacylase activity. The citrate 
synthase reaction was started by the addition of 0.05 ml oxaloacetate. Linear rates 
were obtained for at least 3 minutes (Srere, 1960). 
 
2.2.3.3.2 Complex I 
 
Complex I activity was determined as the decrease in absorbance due to the oxidation 
of NADH (nicotinamide adenine dinucleotide) at 340 nm with 425 nm as the 
reference wavelength (ε= 6.81 mM-1.cm-1). Mitochondria were added to buffer 
containing 25 mM KH2PO4 (pH 7.2), 5 mM MgCl2, 2 mM KCN, 2.5 mg/ml BSA 
fraction V, 0.13 mM NADH, and 65 µM ubiquinone. The NADH-ubiquinone 
oxidoreductase activity was measured for an additional three minutes. Complex I 
activity is measured as rotenone sensitive NADH-ubiquinone oxidoreductase activity 
in oxidative phosphorylation (Birch-Machin et al., 1994). The absorption of this 
complex is detected at wavelengths require to assay complex III, and is blocked by 
rotenone. 
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2.2.3.3.3 Complex II  
 
Complex II activity was determined as the reduction of 2,6-dichlorophenolindophenol 
at 600 nm (ε= 19.1 mM-1 . cm-1). Mitochondria were pre-incubated in buffer 
containing 25 mM KH2PO4 (pH 7.2) and 5 mM MgCl2 at 30ûC for 10 minutes. In 
addition, 2 µg/ml antimycin A, 2 µg/ml rotenone and 50 µM 
dichlorophenolindophenol were added and the baseline rate recorded for 3 minutes. 
The reaction was started with the addition of ubiquinone 65 µM. The enzyme-
catalysed reduction on dichlorophenolindophenol was measured for 5 minutes as 
modified from Birch-Machin et al. (1994). Antimycin A was employed to inhibit 
complex III activity, whilst assaying for complex II. 
 
2.2.3.3.4 Complex III 
 
Complex III activity was determined as the reduction of cytochrome c (III) to 
cytochrome c (II). Activity was measured at 550 nm with 580 nm as the reference 
wavelength (ε= 19 mM-1 .cm-1). The reaction buffer consisted of 25 mM KH2PO4 (pH 
7.2), 5 mM MgCl2, 5.5 mg/ml BSA, 2 µg/ml rotenone, and 15 µM cytochrome c. The 
non-enzymatic rate was measured with the addition of ubiquinol (35 µM) for one 
minute. The increase in absorbance was measured upon the addition of mitochondria. 
Ubiquinol was reduced with excess sodium borohydride and the ubiquinol isolated by 
filtration into ethanol acidified to pH 2 and stored at -80ûC until required as modified 
from Birch-Machin et al. (1994). 
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2.2.3.3.5 Complex IV 
 
Complex IV activity was determined as the oxidation of cytochrome c (II) to 
cytochrome c (III). Activity was measured at 550 nm with 580 nm as the reference 
wavelength (ε=19.1 mM-1 .cm-1). The reaction buffer contained 20 mM KH2PO4 (pH 
7.0) and 15 µM cytochrome c (II). Mitochondria were added and the initial rate was 
measured for one minute. Potassium ferricyanide was added and absorbance 
measured over 5 minutes or until all the cytochrome c (II) was converted to 
cytochrome c (III). Cytochrome c (II) was prepared by the addition of ascorbate to 
cytochrome c (III) (Sigma). Separation of cytochrome c (II) was achieved by 
Sephadex G25 chromatography. Cytochrome c (II) aliquots were stored at -80ûC and 
the protein concentration determined by the method of Bradford immediately before 
enzymatic assays were performed (Bradford, 1976; Birch-Machin et al., 1994) 
 
2.2.4 Free Radical Generation 
 
2.2.4.1  Treatment of MCF-7 cells with AAPH 
 
MCF-7 passage 4 cells were grown to 95% confluence in standard growth medium. 
The culture medium was aspirated and the monolayer treated with trypsin at 37ûC 
until cells detached from the surface of the flask (Section 2.2.1.8). The trypsin was 
inhibited with one volume of growth medium and a cell count taken. Six aliquots 
(300 µl each) of cell suspension were seeded into a 6-well plate (16 cm2) at 6.7 x 104 
cells/well. Cells were grown to 90% confluence. Growth medium was aspirated and 
the monolayer incubated with 20 mM AAPH (2,2′-azobis(2-amido-
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propane)dihydrochloride) in EBSS (Earles balanced salt solution). The monolayer 
was treated for one hour after which the AAPH/EBSS solution was aspirated. The 
culture was thoroughly washed three times with 1 x PBS (pH 7.4). A single well of 
culture was treated with trypsin/EDTA as above and a cell count taken, estimating 7.4 
x 104 cells/ml. A control was cultured without AAPH, the cell count was 1.3 x 105 
cells/ml. Both AAPH treated and control cells were seeded into 12 well plates (3.5 
cm2) at 10,510 and 10,400 cells/well respectively. The population growth study was 
performed as previously described. Cells for the WST-1 assay were seeded at 78 
(control) and 80 (AAPH treated) cells/well (refer to Section 2.2.1.9). 
 
2.2.4.2  Treatment of MCF-7 Cells with DPPH 
 
MCF-7 passage 6 cells were grown to 90% confluence. Culture medium was 
aspirated and 5.0 ml of EBSS containing 250 nM DPPH (1,1-Diphenyl-2-picryl-
hydrazyl) was added. Isopropanol was used as a carrier of DPPH and made up to the 
final volume with EBSS. The culture was incubated for 1 hour and washed three 
times with EBSS. The culture was then treated with trypsin and growth media as 
above and the resulting cell count was 1.5 x 105 cells/ml. DPPH treated cells were 
seeded into 12 well plates at 10,300 cells/well. Cells for the WST-1 assay were 
seeded at 70 cells/well in 96 well plates 0.32 cm2. 
 
2.2.4.3  Treatment of Intact Mitochondria with AAPH 
 
Intact mitochondria were isolated as described in Section 2.2.3.1. Ten µl of 
mitochondrial suspension was placed in a 1.5 ml tube. AAPH (20 mM) was added in 
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1 x PBS buffer to a final volume of 20 µl. The tube was mixed gently by inversion 
and incubated at 37ûC for 1 hour. DNA was isolated using the phenol/chloroform 
method (Section 2.2.2.1) and the mitochondrial genes ND1, COI, Cytb and D-loop 
were amplified. The PCR product was visualized (Section 2.2.2.2) and precipitated 
(Section 2.2.2.6) and sequenced by ABI fluorescent sequencing (Section 2.2.2.8)  
 
2.2.4.4  Treatment of Intact Mitochondria with DPPH 
 
Treatment with DPPH was performed as described for AAPH in Section 2.2.4.3. 
DPPH was dissolved in 5 µl of isopropanol and made up to the final volume with 1 x 
PBS. This gave a final concentration of 250 nm DPPH. 
 
2.2.4.5  AAPH Treatment of DNA 
 
MCF-7 DNA (1.38 µg) was incubated individually with 15 µl of AAPH at 
concentrations 20 mM, 50 mM and 100 mM in 1 x PBS. Incubations were performed 
at 37ûC for one and three hours. The treated DNA was analyzed by electrophoresis 
(Section 2.2.2.2). Ethidium bromide was used to stain the gel and DNA visualized 
under UV light. 
 
 
2.2.4.6  DPPH Treatment of DNA 
 
MCF-7 DNA (2.75 µg) was treated individually with 100 nM, 250 nM and 500 nM of 
DPPH. Isopropanol (5 µl) was used as a carrier and made up to the final volume in 1 
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x PBS. The solution was incubated at 37ûC for one hour. The treated DNA was 
analysed as described in Section 2.2.4.5 
 
2.2.4.7  Continuous Free Radical Assault 
 
MCF-7 passage 7 cells were grown in a T-25 flask to 90 % confluence. The culture 
was treated with trypsin and a cell count estimated to be 4.0 x 105 cells/ml. Six twelve 
well plates were seeded at 10,474 cells/well. To three well plates, AAPH, 2 mM, 4 
mM, and DPPH, 25 nM were added. To the remaining, 1 mM AAPH, 25 nM DPPH 
and a control incubation were performed. Plates were incubated at 37ûC/5% CO2. 
DPPH was dissolved in 0.5 µl isopropanol, mixed with 2 ml of growth medium and 
allowed to evaporate from the culture before the lid was closed. The control was 
performed alongside, and consisted of the addition of 0.5 µl isopropanol alone. Cell 
counts were performed as previously described (Section 2.2.1.9). Treatment with low 
level free radical generator lasted for 72 hours, after which the cultures were washed 
thoroughly with 1 x PBS. Cultures were established from treated cells and grown to 
confluence (average 5 days) in T-75 flasks. DNA was isolated as described 
previously (Section 2.2.2.1) from these cultures for mutation analysis.  
 
 
 
2.2.4.8  Extended MCF-7 Cell Growth 
 
MCF-7 cells (passage 7) were grown to confluence and subcultured for a period of 60 
days. This allowed an approximate 53 population doubling times to take place. This is 
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equivalent to cell culture generation number (Freshney, 2000). Care was taken to 
grow cultures to 85-90% confluence before subculture throughout. DNA was isolated 
from this culture and quantified (Section 2.2.2.1). Mitochondrial genes ND1, CO I, 
D-loop and Cyt b were amplified and sequenced as previously described (Section 
2.2.2.4) for mutation analysis. 
 
2.2.4.9  Genomic DNA Isolation and PCR 
 
DNA was isolated from all free radical generator treated cells and extended MCF-7 
growth cells by the aforementioned phenol/chloroform method as (Section 2.2.2.1). 
PCR amplification and ABI sequencing (Sections 2.2.2.4 and 2.2.2.8) were applied to 
the mitochondrial genes, ND1, Cytb, D-loop and COI. These genes form over one 
third of the mitochondrial genome. 
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3.1 Cell Culture 
 
3.1.1  Isolation of Single Cell Clones 
 
Eleven single clones (B5, B12, C6, C12, D4, D9, E1, E8, F2, F9, G8) were obtained. 
From these, eight single cell clone cultures were established. These excluded clones 
C6, F2 and F9. The yield of single cell clones was not as high as anticipated due to 
some cell clumping during isolation. Figure 3.1 shows isolated single cell clones (A 
and C), and a culture with two cells (B) that was discarded during single clone 
isolation. 
 
     
Figure 3.1. Single cell clone isolation, A, and C, show isolated single cells for 
further culturing, B, shows a discarded culture that contained two cells 
 
The isolated single cell clones began to proliferate after a minimum of 10 days, with 
some taking as long as 15 days. 
 
3.1.2  Growth Morphology 
 
Growth morphology and characteristics were carefully studied. Clone C12 appeared 
to grow in very tight clusters (Figure 3.2 A) even with adequate room to spread out. 
Cultures of this particular clone were seeded in a uniform scatter of cells, but distinct 
clusters began to emerge within two days, favouring cluster growth habit. The cluster 
50 µM 
A B C
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cells were also smaller. This characteristic was not observed in the remaining clones. 
Culture B5 (Figure 3.2 B) grew with notable contact inhibition. This characteristic 
was not observed in other cultures. Cultures G8 (Figure 3.2 C) and E1 (Figure 3.2 D) 
grew in a similar fashion to the MCF-7 original culture (Figure 3.2 E). 
 
 
 
 
  
 
 
Figure 3.2. Cultures of established single cell clones. A, C12 with distinct cluster 
formation; B, B5 with notable contact inhibition; C, G8; D, E1; E, MCF-7 culture from which 
the single clones were derived. 
 
 
3.1.3  Isolation of Non-proliferate Clones 
 
Cell clones C6, F2 and F9 did not proliferate within the 96 well plates after 45 days 
and were discarded. These clones proliferated to approximately 20 cells each clone, 
but did not grow further. DNA was obtained from clone C6, but was not successfully 
amplified. DNA was unable to be isolated from clones F2 and F9. The F2 and F9 
A B
C D E
50 µM 50 µM 50 µM 
50 µM 50 µM
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culture grew to approximately 20-30 cells. The cell morphology for these clones 
appeared to be similar to E1 and G8, no cluster formation or distinct contact inhibition 
was observed. 
 
3.1.4  Cell Proliferation with Trypan Blue 
 
Preliminary growth studies on all viable single cell clone populations were performed. 
The cell cultures were in the second passage following isolation. From these, six 
single cell clones (B5, C12, D4, D9, E1 and G8) were selected for more detailed study. 
Figures 3.3 to 3.5 show the growth patterns of these clones using trypan blue cell 
counting. Figure 3 depicts growth curves of the clones D4 and D9 against the MCF-7 
stock culture. These appear to grow in a similar fashion. Figure 3.4 depicts clones E1 
and G8. Clone G8 displayed an early plateau phase, three factors below MCF-7. 
Clone E1 show a similar growth curve to that of the MCF-7 stock culture. Clones B5 
and C12 (Figure 3.5) plateau at an earlier stage (factor of 102) than MCF-7. The 
average R2 values for the trypan blue method of cell proliferation was 0.9735. The lag 
phase for B5, G8 and MCF-7 is approximately 24 hours. The lag phase for the 
remaining cultures was much shorter, or non-existent. All cultures were seeded at the 
same cell density, deviating less than 100 cells/well (Section 2.2.1.9). 
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Figure 3.3. Population growth curve of single cell 
clones D9  (R2=0.9665) and D4  (R2=0.9953), with 
the standard, MCF-7  (R2=0.9995). Data shown as 
mean + SE 
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Figure 3.4. Population growth curve of clones E1  
(R2=0.9925) and G8  (R2=0.8957), with the standard, 
MCF-7 . Data shown as mean + SE 
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Figure 3.5. Population growth curve of clones B5   
(R2=0.9825) and C12 (R2=0.9824), with the standard, 
MCF-7  . Data shown as mean + SE 
 
 
 
 
3.1.5  Cell Proliferation with WST-1 
 
Figures 3.6 shows the colour change during the WST-1 assay. This is due to a 
cleavage of tetrazolium salt, producing a formazan product. GM was aspirated and 
replaced by the phenol free medium (pale yellow). The WST-1 reagent was a pale red 
colour, that became progressively more orange as the formazan adduct was produced. 
A UV visible microplate reader (Bio-Tek instruments) monitored this colorimetric 
shift. 
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Figure 3.7 and 3.8 display growth curves derived from the absorbance values for the 
WST-1 assay. Cell number was estimated from a calibration curve of known cell 
concentration. Clone B5 displays the fastest cell population growth, and C12 the 
slowest. This is consistent with the growth curves constructed from the trypan blue 
cell estimates. 
Figure 3.6.  The WST-1 assay. Lane 1, wells seeded at 75 
cells/well. Measurement taken at 24 hours; lane 2, 40 hours;
lane 3, 98 hours; lane 4, 119 hours; lane 5, 155 hours; lane 6, 
203 hours; lane 7, 301 hours; lane 8, 350 hours; lane 9, 398
hours; lane 10, 449 hours; lane 11, cells growing, not yet 
assayed; lane 12, control well for each measurement. 
 1      2       3      4       5      6       7      8       9     10    11   12
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Figure 3.7. WST-1 growth curve of clones. E1   
(R2=0.9706) and G8  (R2=0.8058), with the 
standard, MCF-7  (R2=0.8760). Data shown as 
mean + SE 
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Figure 3.8. WST-1 growth curve of clones. C12  
(R2=0.8448) and B5  (R2=0.8705), with the standard, 
MCF-7 . Data shown as mean + SE 
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3.1.6  Comparison of Cell Proliferation Estimate Techniques 
 
Table 3.1 and Figure 3.9 summarise the growth rates of different cell clones. B5 
appears to be the fastest growing clone with a population doubling time (PDT) of 
25.50 (trypan blue) and 25.75 (WST-1). This is followed by MCF-7 (27.00, 27.08), 
DPPH treated (27.00, 27.50), AAPH treated (28.00, 29.00), E1 (28.79, 32.41), G8 
(31.76, 30.19), D4 (37.5, -), D9 (37.5, -) and the slowest, C12 (41.00, 35.00) (Table 
3.1). Agreements between the two techniques for estimating PDT tend to decrease as 
PDT increases.  
 
 
Table 3.1. Trypan blue and WST-1 estimates of PDT (hours). 
 
Cell culture    Trypan Blue   WST-1 
B5     25.5    25.75 
MCF-7 (standard)   27.00    27.08 
DPPH treated    27.00    27.50 
AAPH treated    28.00    29.00 
E1     28.79    32.41 
G8     31.76    30.19 
D4     37.50    - 
D9     37.50    - 
C12     41.00    35.00 
MCF-7 estimate from ATCC in 29.00 hours (method unknown) 
 
Figure 3.9 represents the relative population doubling times comparing trypan blue 
and WST-1 methods.  
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Figure 3.9. Comparison of trypan blue and WST-1. Comparative 
population doubling times of single cell clones and the standard MCF-7 
using trypan blue cell viability counting and the WST-1 biochemical 
assay 
 
 
3.2 DNA Analysis 
 
3.2.1  DNA Isolation and Quantification 
 
Figure 3.10 displays the quality of isolated DNA from the MCF-7 stock culture and 
derived single cell clones. Some protein contamination was present (Figure 3.10, lane 
5); however, this did not interfere with amplification of DNA by PCR. 
 
 
Figure 3.10. Isolated cell culture DNA. Lane 1, 
molecular marker λHindIII/EcoRI; lane 2, MCF-7; 
lane 3, G8; lane 4, C12; lane 5, B5; lane 6, E1; lane 7 
and 8, Extracted MCF-7 DNA from cells treated with  
AAPH (20 mM). 
 
1          2        3        4         5        6         7        8   
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Table 3.2 displays the concentration of isolated DNA. Purity was determined by the 
ratio between the absorbance at 260 nm and 280 nm. An increase above 1.8 indicates 
contamination by phenol, below is indicative of protein contamination. 
 
Table 3.2. Genomic DNA quantification. 
 
DNA  A260  A280  A260/280   Quantity (µg/µl) 
MCF-7 0.025  0.013  1.92   0.125 
E1  0.130  0.077  1.69   0.650 
G8  0.021  0.011  1.91   0.105 
B5  0.093  0.049  1.90   0.465 
C12  0.025  0.015  1.67   0.125 
AAPH  0.055  0.029  1.90   0.275 
Note: AAPH denotes DNA derived from AAPH treated MCF-7 cells 
 
 
3.2.2  PCR of the Mitochondrial Genome 
 
PCR was performed on all genes of the mitochondrial genome, in both forward and 
reverse direction. All supplementing PCR electrophoresis gels can be viewed in 
Appendix C (PCR and sequencing). Figures 3.11, 3.13 and 3.15 show gels of PCR 
amplicons and the corresponding ABI chromatograms are located directly beneath 
them. These sequences show varying levels of mitochondrial DNA heteroplasmy. 
  
3.2.3   ABI and Licor Sequencing 
 
The establishment of the MCF-7 baseling was achieved by employing Licor and ABI 
sequencing. The remaining sequencing was largely achieved with the ABI system. 
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3.2.3.1  Establishing the MCF-7 Baseline 
 
The MCF-7 mitochondrial genome was sequenced, and determined to have 26 base 
changes in contrast to the NC_001078 homo-sapiens genome (NCBI, April, 2005). 
Table 3.3 lists these changes and their respective amino acid changes. This baseline 
was used to determine changes between the MCF-7 stock mtDNA and single cell 
clones. 
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3.3.2.2  Heteroplasmy Between Single Cell Clones 
 
Genes ND6 and ATPase (Figures 3.12 and 3.14) were sequenced with both ABI Big 
dye terminator and Licor fluorescent sequencing. The Cytb gene (Figures 3.16 to 
3.19) was sequenced with ABI alone. All sequencing was performed in the forward 
and reverse direction. A summary of replicates for these sequences can be found in 
Table 3.3 
 
 
 
Figure 3.11. A PCR of the ND6 gene. Lane 1, molecular marker 
λHindIII/EcoRI, lane 2 and 3, C12; lane 4 and 5, MCF-7; lane 6 and 7, E1; 
lane 8 and 9, B5; lane 10, negative control. 
 
 
 
                
Figure 3.12. C12 ABI chromatogram of the ND6 gene from the forward 
direction, A. ABI sequence showing heteroplasmy; B. Licor sequence of the 
MCF-7 stock. The arrow indicates heteroplasmy between the T and G 
nucleotide bases (bp 14300). 
 
 
705 bp 
      1          2           3           4           5         6           7           8          9          10 
A  G  C  T 
A B
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Figure 3.13. A PCR product of the ATPase gene. Lane 1, molecular marker 
λHindIII/EcoRI, lane 2 and 3, C12; lane 4 and 5, MCF-7; lane 6 and 7, E1; lane 
8 and 9, B5; lane 10, negative control. 
 
       
Figure 3.14.  ABI chromatographs of a portion of the ATPase6 gene displaying heteroplasmy (bp 
9119) A, B5; B, C12. The arrow indicates heteroplasmy between the C and T nucleotide bases (reverse 
sequence shown). 
 
 
 
Figure 3.15. A PCR product of the Cytb gene. Lane 1, molecular marker 
λHindIII/EcoRI, lane 2 and 3, MCF-7; lane 4 and 5, G8; lane 6, B5; lane 7, 
C12; lane 8, E1; lane 9, negative control . The arrows indicate the PCR 
product for clones B5 and C12 harbouring different DNA heteroplasmy. 
 
Figures 3.16 to 3.18 (below) show ABI chromatograms of the Cytb gene (reverse 
sequence) for clone B5 (Figure 3.16), MCF-7 original culture (Figure 3.17) and clone 
C12 (Figure 3.18). These figures demonstrate a level of heteroplasmy that is present 
B5 C12 
1385 bp 
870 bp 
      1          2           3           4           5         6           7           8          9          10 
      1            2           3             4           5           6            7          8           9     
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in clone B5, minimally present in the original MCF-7, but absent in clone C12. Clone 
E1 exhibited comparable heteroplasmy to the stock MCF-7. Clone G8 displayed 
mimimal heteroplasmy (Appendix C, PCR and sequencing). The level of 
heteroplasmy is estimated to be 15-20% (Clone B5, Figure 3.16) from studies 
performed in our laboratory (Angie Sin, personal communication).  
 
 
Figure 3.16. ABI Chromatograph of a portion of the 
Cytb gene. (bp 15807) The arrow indicates the B5 clone 
DNA heteroplasmy between the G and A bases (reverse 
sequence shown). 
 
 
Figure 3.17. ABI Chromatograph of a portion of the Cytb 
gene. MCF-7 Cytb DNA displaying a degree of heteroplasmy 
(reverse sequence shown). 
 
 
 
Figure 3.18. ABI Chromatograph of a portion of the 
Cytb gene. C12 clone DNA showing a lack of 
heteroplasmy (reverse sequence shown). 
 
 
Table 3.4 summarises the relationship between the degree of mitochondrial DNA 
heteroplasmy and the samples harbouring the change. All clones and the MCF-7 stock 
present DNA heteroplasmy for the ATPase and ND6 genes. The Cytb gene 
Chapter 3 - Results 
 63
heteroplasmy is only present in the MCF-7 stock and clones B5 and E1. It is absent in 
clone G8 and C12. 
 
Table 3.4.  Summary of Mitochondrial Heteroplasmy. 
 
Nucleotide Gene    Degree of    Samples         Amino acid 
    Heteroplasmy  presenting  change 
9119  ATPase6 50%   MCF-7, B5  no change 
       C12, E1, G8 
 
14300  ND6  20%   MCF-7, B5  Y→STOP 
       C12, E1, G8 
 
15807  Cytb  15-20%  MCF-7, B5, E1 A→T 
 
Confirmation for the sequencing results in Table 3.4, including supporting sequences 
can be found in Appendix C (PCR and sequencing) including a full list of sequencing 
replicas. 
3.3     Oxidative Phosphorylation 
 
3.3.1  Isolation of Intact Mitochondria 
 
Table 3.5 shows the yield of protein from extracted mitochondria in relation to the 
number of cells used for isolation. This was determined after sonication and freeze-
thawing in which the mitochondrial proteins of oxidative phosphorylation were 
accessible to quantification and enzyme assay. Clone E1 yielded a much higher 
amount of protein (683 µg/ml) for the number of cells used for isolation (1.1 x 106). 
Mitochondria for all samples were isolated concurrently. 
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Table 3.5. Protein yield from mitochondrial extraction relative to cell number. 
 
Cell clone Quantity of cells for isolation  Protein yield µg/ml 
MCF-7 1.6 x 106     170  
E1  1.1 x 106     683  
G8  1.0 x 106     175  
B5  6.9 x 105     317 
C12  1.6 x 106     216  
 
Enzyme assays were performed for complexes I-IV of the respiratory chain involved 
in the process of oxidative phosphorylation. Figure 3.19 shows the calibration curve 
from which the protein contents of mitochondrial extract were determined after intact 
mitochondria isolation. 
 
3.3.2  Bovine Serum Albumin Standard Curve 
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3.3.3  Assay for Citrate Synthase 
 
The first step for enzyme assay was a measurement of the relative levels of citrate 
synthase (CS) in the mitochondrial extracts. This is indicative of mitochondrial copy 
Figure 3.19. BSA (fraction V) standard 
curve. various concentrations were measure at 
595 nm. The R2 value indicates a strong curve 
fit 
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number (Srere, 1960) and hence important in standardizing clone fractions by the 
amount of target enzyme present. The CS assay utilized the reduction of DTNB to 
mercaptide ion (Figure 3.20) by an increase in absorbance in µmol/sec/mg protein 
(Table 3.6).  
 
S
COO-
S
COO-
O2N NO2
COO-
S S RO2N
S
COO-
NO2+ RSH H+
Mercaptide ion5,5'-dithiobis-(2-nitrobenzoate)  
 
Figure 3.20. Citrate synthase assay. The citrate synthase assay was performed by the reduction of 
5,5-dithiobis-(2-nitrobenzoate) (DTNB) to the mecaptide ion product, resulting in an absorbance 
increase at 412 nm 
 
 
Table 3.6 involved the addition of equal amount of protein (as determined from the 
BSA standard curve) for enzyme assay. From this, the specific activity of citrate 
synthase was determined in µmol/sec/mg protein. This gives comparative activity of 
samples with the same amount of protein. 
 
Table 3.6. Citrate Synthase enzyme activity. 
 
Cell culture Enzyme activity/ml   Specific activity 
  µmol/sec/ml (+ SEM)  µmol/sec/mg protein (+ SEM) 
MCF-7 1.84 x 10-4 +/- 8.28 x 10-5  0.018 +/- 8.12 x 10-3 
 
E1  2.15 x 10-4 +/- 5.31 x 10-5  0.016 +/- 3.89 x 10-3 
 
G8  7.36 x 10-5 +/- 1.42 x 10-5  8.41 x 10-3 +/- 1.62 x 10-3 
 
B5  2.15 x 10-4 +/- 7.08 x 10-5  0.017 +/- 5.58 x 10-3 
 
C12  7.36 x 10-5 +/- 0   6.81 x 10-3 +/- 0 
Values represent averages (+ SE) from triplicate enzyme assays 
 
 
Chapter 3 - Results 
 66
3.3.4  Complex I 
 
Complex I is encoded by the mitochondrial genes ND1, ND2, ND3, ND4, ND5 and 
ND6 (MITOMAP). Complex I was assayed by the oxidation of NADH to NAD+ 
(Figure 3.21) giving an increase in absorbance at the rates indicated in Table 3.7. This 
and subsequent assays have been standardized with CS, displaying activity both 
before and after standardisation. Clone C12 had the highest activity at 82.23 + 9.23 
µmol/sec/mg protein with B5 the lowest 20.00 + 1.35 µmol/sec/mg protein. 
N
NH2
O
H
+ N
+
NH2
O
NADH NAD+  
Figure 3.21. The reduction of nicotinamide adenine 
dinucleotide (NADH) to NAD at 340 nm (425 nm reference) by 
complex I. 
 
Table 3.7. Complex I - NADH dehydrogenase enzyme activity. 
 
Cell culture Enzyme activity/ml Specific activity     Standardize with 
  µmol/sec/ml  µmol/sec/mg protein     citrate synthase  
            µmol/sec/mg protein 
MCF-7 1.02 x 10-3  0.75 +/- 0.11      41.67 +/- 6.11  
  +/- 1.51 x 10-4 
 
E1  2.38 x 10-3   0.70 +/- 0.095      43.75 +/- 5.94 
  +/- 3.24 x 10-4 
 
G8  8.60 x 10-4  0.61 +/- 0.061      72.53 +/-7.25 
  +/-8.51 x 10-5 
 
B5  7.55 x 10-4  0.34 +/- 0.023      20.00 +/- 1.35 
  +/-5.07 x 10-5 
 
C12  9.74 x 10-4  0.56 +/- 0.063      82.23 +/- 9.23 
  +/-1.08 x 10-4 
Values represent averages (+ SE) from triplicate enzyme assays. Enzyme activity/ml is activity/ 
ml final reaction volume used in assay 
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3.3.5  Complex II 
 
Complex II is entirely encoded by nuclear DNA (nDNA). Activity for this complex 
was high relative to the mitochondrial encoded complexes. E1 had the highest activity 
at 629.38 µmol/sec/mg protein. The activity for clone B5 was markedly lower at 
148.82 µmol/sec/mg protein (Table 3.8). Complex II is partially responsible for 
replenishing the quinone pool.  
 
Table 3.8. Complex II  Succinate dehydrogenase enzyme activity. 
 
Cell culture Enzyme activity/ml Specific activity     Standardize with 
  µmol/sec/ml  µmol/sec/mg protein     citrate synthase  
            µmol/sec/mg protein 
MCF-7 0.016   4.78 +/- 1.32      265.56 +/- 73.33 
  +/- 4.5 x 10-3 
 
E1  0.055   10.07 +/- 0.66      629.38 +/- 41.25 
  +/- 3.58 x 10-3 
 
G8  8.19 x 10-3   2.34 +/- 0.41      278.24 +/- 48.75 
  +/- 1.44 x 10-3 
 
B5  0.012   2.53 +/- 0.28      148.82 +/- 16.47 
  +/- 1.33 x 10-3 
 
C12  0.013   4.01 +/- 0.59      588.84 +/- 86.64 
  +/- 1.92 x 10-3 
Values represent averages (+ SE) from triplicate enzyme assays. Enzyme activity/ml is activity/ 
ml final reaction volume used in assay 
 
 
3.3.6  Complex III 
 
Complex III is partially encoded by mitochondrial gene Cytb, the remaining genes are 
of nuclear origin. Figure 3.22 highlights two essential components for the assay of 
complex III. Rotenone is required to block complex I activity, detectible at 600 nm. 
Without this component, the enzyme activity for complex III would represent a 
Chapter 3 - Results 
 68
combination of complex I and complex III activities. The substrate for complex III, 
2,6-dichlorophenol indophenol is readily detected at 600 nm. Clone G8 had the 
highest activity for complex III (592.15 +/- 24.97 µmol/sec/mg protein) whilst clone 
C12 was unable to be detected (Table 3.9). 
 
OO
O
O
O
O
H
H
Rotenone
                     
N
O
ClCl
ONa
2,6-dichlorophenol indophenol 
 
Figure 3.22. Essential components of complex III enzyme assay. A, 
Rotenone blocks complex I to assay for complex III by the reduction 
of 2,6-dichlorophenol indophenol (B) at 600 nm 
 
 
Table 3.9. Complex III  Ubiquinol cytochrome c- oxidoreductase enzyme activity. 
 
Cell culture Enzyme activity/ml Specific activity     Standardize with 
  µmol/sec/ml  µmol/sec/mg protein     citrate synthase  
            µmol/sec/mg protein 
MCF-7 1.03 x 10-4  0.061 +/- 0.039     3.39 +/-2.17 
  +/- 6.65 x 10-5 
 
E1  9.58 x 10-3  3.05 +/- 0.36      190.63 +/- 22.5 
  +/- 1.24 x 10-3 
 
G8  8.72 x 10-3  4.98 +/- 0 0.21      592.15 +/- 24.97 
  +/- 3.62 x 10-4 
 
B5  0.0146   5.76 +/- 0.40      338.82 +/- 23.53 
  +/- 1.02 x 10-3 
 
C12  Could not detect activity 
Values represent averages (+ SE) from triplicate enzyme assays. Enzyme activity/ml is activity/ 
ml final reaction volume used in assay 
 
A B
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3.3.7  Complex IV 
 
Complex IV is encoded by the mitochondrial genes COI, COII, and COIII 
(MITOMAP). Complex IV activity is monitored by activity of cytochrome c oxidase, 
by the oxidation of cytochrome c. Enzyme activities are summarised in Table 3.10. 
 
Table 3.10 Complex IV  Cytochrome c oxidase enzyme activity. 
 
Cell culture Enzyme activity/ml Specific activity     Standardize with 
  µmol/sec/ml  µmol/sec/mg protein     citrate synthase  
            µmol/sec/mg protein 
MCF-7 0.013   7.65 +/- 0.94      425 +/- 52.2 
  +/- 1.6 x 10-3 
 
E1  8.67 x 10-3  2.54 +/- 0.38      158.75 +/- 23.75 
  +/- 1.30 x 10-3 
 
G8  could not detect activity 
 
B5  6.5 x 10-3  2.05 +/- 0.22      120.59 +/- 12.94 
  +/- 7.00 x 10-4 
 
C12  5.2 x 10-4  0.24 +/- 0.14      35.24 +/- 20.56 
  +/- 3.00 x 10-4 
Values represent averages (+ SE) from triplicate enzyme assays. Enzyme activity/ml is activity/ 
ml final reaction volume used in assay 
 
 
3.3.8 Summary of Relative Enzyme Activities 
 
Figure 3.23 is a schematic representation of complex I-IV enzyme activities, with the 
greatest activity at the top and the lowest or undetected activity at the bottom. 
Interestingly, the fastest single cell clone (B5) is not enzymatically superior 
throughout all complexes and has the lowest activity in complexes I and II. The 
slowest single cell clone (C12) has very high activity for complexes I and II. The 
reverse occurs in complexes III and IV, in which B5 activity increases and C12 
activity decreases. 
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Figure 3.23. Schematic of relative enzyme activities with greatest activity at the top. There 
was no detectable activity for C12 in complex III or G8 in complex IV 
 
 
Table 3.11 provides a summary of the relationship between mitochondrial 
heteroplasmy and cell clone population doubling time.
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3.4 Reactive Oxygen Species 
 
 
3.4.1  Growth Morphology 
 
The growth morphology changed significantly in some of the radical treatments. 
Treatment of the MCF-7 original culture with 20 mM AAPH for 1 hour did not appear 
to change cell size or morphology (Figure 3.24, A). Conversely, treatment with 2 mM 
(B) and 4 mM (C) AAPH for 72 hours dramatically changed cell appearance but not 
size. The addition of 2 mM AAPH induced a level of nuclear vacuolization, 
suggesting the cell may be undergoing apoptosis. The addition of 4 mM AAPH 
reduced the cell population ten-fold. Upon cell growth, distinct clusters emerged in an 
analogous manner to that of the C12 single cell clone (Section 3.1.1). 
 
 
Figure 3.24. AAPH treated cells. A, cell proliferation from a culture treated with 20 mM AAPH 
incubated for 1-hour; B, cell morphology from 2 mM AAPH incubated for 72 hours, there is notable 
cytoplasmic vacuolation and granulation;  C, cluster morphology of cell culture grown from 4 mM 
AAPH treated cells. 
 
Treatment of the original MCF-7 culture with DPPH at 250 nM (Figure 3.25, A) 
appeared to induce a slightly higher level of contact inhibition in approximately 20 % 
of the culture at confluence. A DPPH level of 25 nM (Figure 3.25, B, C) induced a 
similar morphology to that observed in the 2mM and 4 mM AAPH cultures. The 
control did not share these characteristics 
 
50 µM50 µM 50 µM 
A B C
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Figure 3.25. DPPH treated cells. A, cell proliferation from culture treated with 250 nM DPPH 
incubated for 1-hour; B and C, cell proliferation from 25 nM incubation over 72 hours. 
 
MCF-7 cell were grown over an extended period of time. The morphology of the 
MCF-7 cells changed slightly (Figure 3.26) as the cells became elongated. The culture 
still grew as described in Section 3.1.2. DNA was successfully isolated from this 
culture and amplified for the same mitochondrial genes as the radical treated cells 
(ND1, COI, Cytb and D-loop). This was performed with particular interest in the D-
loop region, to compare with the range of estimates mitochondrial mutation rate. The 
MCF-7 culture in Figure 3.26 was in its 53rd generation.  
 
 
Figure 3.26. Slightly 
elongated cells observed for 
MCF-7 in 53rd generation. 
 
 
3.4.2  Cell Proliferation  
 
Growth curve methods and statistical analysis were performed as described in 
Sections 3.1.4 and 3.1.5. 
 
50 µM 50 µM 50 µM 
A B C
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Figure 3.27 shows the growth curves obtained from population studies using trypan 
blue cell viability dye and standard cell counting. The 20 mM AAPH treated culture 
shows a lower plateau phase, potentially due to a reduction in the surviving fraction, 
inducing a longer lag phase. This is confirmed by the WST-1 cell proliferation curve. 
The 250 nM DPPH treated culture follows the MCF-7 stock culture in Figure 3.27, 
but deviates between the AAPH treated and the MCF-7 stock in Figure 3.28. The 
experiments were performed alongside each other, with three replicas for Figure 3.27 
(trypan blue) and eight replicas for Figure 3.28 (WST-1). A longer lag phase appears 
in Figure 3.28, after which the culture conforms to the MCF-7 stock after a period of 
250 hours. 
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Figure 3.27. Population growth curve. MCF-7 ( , 
passage 5 R2=0.9995); MCF-7 cells treated with 20 
mM AAPH (R2=0.9995); MCF-7 cells treated with 
250 nM DPPH  (R2=0.9959). Data shown as mean + 
SE. 
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Figure 3.28. WST-1 Population growth curve. MCF-7 
( , passage 5 R2=0.8760); MCF-7 cells treated with 20 
mM AAPH  (R2=0.8729); MCF-7 cells treated with 250 
nM DPPH  (R2=0.9980). Data shown as mean + SE. 
 
 
 
3.4.3 Cultures under Continuous Free Radical Assault 
 
 
Figure 3.29 shows the difference in cell proliferation between the cultures treated with 
low-level free radical generators and the MCF-7 control. These were seeded at a 
higher level (10,000 cells/3.5 cm2) as cell proliferation was unable to be detected at 
lower levels. The culture treated with 1 mM AAPH and 25 nM DPPH was more 
proliferative than that treated with 25 nM DPPH alone. 
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Figure 3.29. Response to free radical generator. MCF-7 cells ( , passage 8) treated 
with low level radical; AAPH (  , 1 mM); DPPH (  , 25 nM); AAPH (1 mM)/ DPPH 
(25 nM,  ). Data shown as mean + SE. 
 
 
3.4.4  DNA Isolation and Quantification 
 
Isolation of cell line DNA from MCF-7 cells treated with various levels of free 
radicals was successful. Figure 3.30 depicts the quality of DNA obtained. Table 10 
gives the absorbance values for DNA samples at 260 and 280 nm.  
 
 
 
 
Figure 3.30. DNA isolated from radical study. Lane 1 
λHindIII/EcoR1 marker, lane 2 and 3, MCF-7 cell DNA (53rd 
generation), lane 4 and 5, AAPH treated cell DNA; lane 6 and 
7, DPPH treated cell DNA; lane 8 and 9, AAPH/DPPH treated 
cell DNA. 
 
      1         2         3         4         5        6         7         8        9       
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Table 3.12. Genomic DNA quantification. 
 
DNA   A260  A280  A260/A280 Quantity (µg/µl) 
MCF-7 *  0.130  0.107  1.21  0.650 
AAPH 2 mM  0.140  0.108  1.30  0.700 
AAPH 4mM  0.013  0.008  1.63  0.065 
DPPH 25 nM  0.024  0.014  1.71  0.120 
AAPH(1 mM)/ 0.009  0.004  2.25  0.045 
DPPH(25 nM) 
AAPH and DPPH refer to MCF-7 cells treated with free radicals at the indicated concentrations 
*MCF-7 cells in their 53rd generation 
 
 
PCR products were obtained for genes ND1, COI, Cytb and D-loop for all DNA 
sample in Table 3.12. These PCR products are from the low free radical generator 
concentrations with continuous treatment and the MCF-7 cells grown over an 
extended period of time. Figure 3.31 shows the PCR product from the Cytb gene 
from the low-level free radical generator study. Figures 3.32, 3.33 and 3.34 show the 
PCR product for the low-level radical generator study for genes ND1, COI and D-
loop, respectively. Additional PCR products for the mitochondrial DNA extraction 
and one hour free radical generator incubation can be seen in Appendix C (PCR and 
sequencing). ABI chromatograms for these PCR products can also be found in 
Appendix C. 
 
Figure 3.31. PCR precipitate of the Cytb gene. Lane 1, 
molecular marker λHindIII/EcoRI; lane 2, MCF-7; lane 3, 
AAPH (2 mM) treated cell culture DNA; lane 4, DPPH 
(25 nM) treated cell culture DNA; lane 5,  AAPH (1 mM) 
and DPPH (25nM) treated cell DNA, lane 6, negative 
control. 
     1           2          3           4          5          6          7         
Chapter 3 - Results 
 78
 
 
Figure 3.32. PCR of the ND1 gene. Lane 1, molecular marker λHindIII/EcoRI, 
lane 2 and 3, MCF-7; lane 4 and 5, AAPH (2 mM) treated cell culture DNA; 
lane 6 and 7, DPPH (25 nM) treated cell culture DNA; lane 8 and 9, AAPH (1 
mM) and DPPH (25nM) treated cell culture DNA; lane 10, negative control 
 
 
 
 
 
 
 
 
 
 
Figure 3.33. PCR precipitate of the COI gene. Lane 1, molecular marker 
λHindIII/EcoRI; lane 2 and 3, MCF-7; lane 4 and 5, AAPH (2 mM) treated 
cell culture DNA; lane 6 and 7, DPPH (25 nM) treated cell culture DNA; lane 
8 and 9,  AAPH (1 mM) and DPPH (25nM) treated cell culture DNA; lane 10, 
negative control 
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Figure 3.34. PCR precipitate of the D-loop gene. Lane 1, molecular marker 
λHindIII/EcoRI; lane 2 and 3, MCF-7; lane 4 and 5, AAPH (2 mM) treated 
cell culture DNA; lane 6 and 7, DPPH (25 nM) treated cell culture DNA; lane 
8 and 9, AAPH (1 mM) and DPPH (25nM) treated cell culture DNA; lane 10, 
negative control 
 
 
3.4.5  AAPH and DPPH Treatment of DNA 
 
Figure 3.35 demonstrates the adverse effect AAPH has on DNA, making it a potential 
candidate for DNA mutation. Figure 3.36 demonstrates possible degradation at 500 
nM treatment of MCF-7 DNA with DPPH. This experiment simply shows the 
negative interaction of these two radicals have with mitochondrial DNA. For AAPH, 
this has been well documented (Kristal et al., 1994). For DPPH, it is largely unknown 
whether any deleterious effects may be induced by its presence. 
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3.4.6  AAPH and DPPH Treatment of Isolated Mitochondria 
 
Isolated intact mitochondria were treated with both AAPH (20 mM) and DPPH (250 
nM) for 1 hour at 37ûC. DNA was isolated from these mitochondrial fractions by 
phenol/chloroform extraction (Section 2.2.2.1). The mitochondrial genes ND1, COI, 
Cytb and D-loop were amplified by PCR and sequenced using ABI fluorescent 
sequencing. No DNA base modification or DNA heteroplasmy was observed for these 
genes. Additional PCR products and sequences from this study can be found in 
Appendix C (PCR and sequencing). 
 
3.4.7  Transformation of the MCF-7 Cell Line with AAPH 
 
Figure 3.37 B shows MCF-7 cells that have undergone transformation with 4 mM 
AAPH. A clustered morphology is observed which is very similar to the C12 clone 
 
Figure 3.35. AAPH treated DNA. Lane 
1, molecular marker λHindIII/EcoRI; lane 
2, MCF-7 DNA; lane 3, MCF-7 DNA 
with 20 mM AAPH; lane 4, 50 mM 
AAPH; lane 5, 100 mM AAPH; lane 6, 
MCF-7 DNA, incubated for 2 hours. 
Figure 3.36. DPPH treated DNA. Lane 
1, molecular marker λHindIII/EcoR1; 
lane 2, MCF-7 DNA; lane 3, MCF-7 
DNA with 500 nM DPPH; lane 4, 250 
nM DPPH; lane 5, 100 nM DPPH; lane 6, 
MCF-7 DNA, incubated for 2 hours 
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(Figure 3.37 A) isolated from the MCF-7 stock culture. The C12 clone did not 
undergo any radical treatment. 
 
Figure 3.37. Potential transformation of MCF-7 cells with AAPH. A, 
C12 isolated single cell clone from MCF-7 stock, B, MCF-7 stock treated 
with 4 mM AAPH over 72 hours. 
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4.1 MCF-7 Growth Characteristics 
 
The mammary epithelial cell line MCF-7 is widely used as a cell line model and is 
well characterized (Sutherland et al., 1983; Taylor et al., 1983; Taylor et al., 2001; 
Devarajan et al., 2002; Hand and Craven, 2003; Zou and Matsumura, 2003; Lacroix 
and Leclercq, 2004; Zivadinovic et al., 2004) It has been used to test the effect of 
reactive oxygen species in cell cultures (Chang et al., 2002; Hand and Craven, 2003). 
The MCF-7 cell line has particular features such as subpopulations (Zou and 
Matsumura, 2003). These sub-populations of MCF-7 may posses DNA variation and 
produce different levels of reactive oxygen species as some cultures were shown to 
proliferate faster than others.  
 
4.1.1 Growth Characteristics of Single Cell Clones 
 
In order to obtain genetically homogenous cell lines, single cell clones were isolated 
from the MCF-7 stock. Cell proliferation of single cell clones demonstrated different 
growth patterns between cultures. Further, markedly different growth morphology 
was also observed. In particular, the clustered morphology of the C12 clone was 
distinctive. This clone was the slowest to proliferate (PDT 41 hours), which may be 
due to competition for nutrient from the culture media because of the tight clustering 
growth habit, a difficulty in proliferation due to limited space within the cluster, or 
DNA mutation. In contrast, clone B5 was the most proliferative (PDT 25.5 hours) and 
displayed contact inhibition, and clone G8 (PDT 31.76 hours) with a moderate growth 
rate exhibited a slightly clustered morphology. Thus, the growth habit of a cell line 
may reflect the speed in which a cell population will proliferate. 
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Clone C12 displayed cluster morphology, which was concomitant with reduced 
mtDNA copy number indicated by a lower activity of citrate synthase in this culture 
(Chapter 3, Table 3.6). Citrate synthase activity is an indicator of mtDNA copy 
number. Further, clone G8 exhibited a tendency toward the cluster morphology 
(Figure 3.2C) and also has reduced mtDNA copy number. Lowering of mtDNA copy 
number and the cluster morphology were observed in a culture of human diploid 
fibroblasts that had undergone transformation by SV-40 Torroni et al. (1990). It is 
possible that the C12 culture may be a transformed cell culture. Clone C12 (Figure 
3.37 A) displayed a lack of heteroplasmy within the Cytb gene (bp 15807), which was 
present in other clones. However, this does not appear to be related to the favour of 
cluster formation. 
 
4.1.2 Isolation of Non-proliferative Single Cell Clones 
 
Single cell clones that failed to proliferate after 45 days (C6, F2, F9) may have 
harboured mitochondrial DNA mutation or heteroplasmy that prevented proliferation 
and facilitated cell death. Enriquez et al. (2000) determined the rate of trans-
complementation of mitochondrial DNA carrying a homoplasmic mutation A8344G 
in which the recipient trans-complementing clones were notably sluggish and 
experienced substantial cell death (22-28%) (Enriquez et al., 2000). Such mutation 
may be significant in impairing the function of oxidative phosphorylation. A similar 
study described non-proliferative growth curves in human muscle and myoblast cells 
resulting from a G6930A mitochondrial mutation, which produced a stop codon, 
terminating 170 amino acids from the COX I gene product (Bruno et al., 1999). 
Hence, a difficulty encountered in using a cell line model (with single cell clone 
Chapter 4 - Discussion 
 85
isolation) to study mtDNA mutation is the potential for mutant cells to be non-
proliferate and/or have a high rate of cell death. Therefore, natural variation between 
single cell clones may be difficult to obtain. The severity of mitochondrial defect 
depends largely on the nature of the mutation, and also the ratio of mutant and wild 
type DNA, i.e. the level of mitochondrial heteroplasmy (Bruno et al., 1999; Quintana-
Murci et al., 2001). Nuclear mutation may also have been present in non-proliferative 
clones, thereby altering OXPHOS efficiency and lowering energy production required 
for proliferation. 
 
It is possible that sub-populations exist within the MCF-7 cell line that are non-
proliferative. It is unknown if this is due to a mitochondrial defect because it was not 
possible to isolate the DNA from these cells for analysis. Studies using human 
fibroblasts carrying NARP (neurologic muscle weakness, ataxia and retinitis 
pigmentosa) G8993C (85-90% mtDNA) indicate slowly growing cells contained little 
or no mtDNA (Vergani et al., 1999). This may have been a factor in the inability to 
isolate mtDNA from the limited proliferation cultures. An additional aspect to 
consider is the phenomenon of cancer cell senescence. Cancer cell senescence is a 
tumour suppressive mechanism. Senescence can be divided into two categories; 
replicative senescence (shortening of the chromosomes telomeres) and DNA damage 
preventing cell cycle progression (Langdon, 2004). As viable single cell clones were 
isolated, it is unlikely the former mechanism of senescence is active, though the latter 
mechanism may be involved as the non-proliferative cells remained alive for at least 
one month. This is in agreement with the observation of senescence cell growth arrest 
at G1 but remaining metabolically active and thus, being sustained for a period of time 
(Langdon, 2004). Moreover, ROS have been implicated in cellular senescence 
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(Behrend et al., 2003; Hand and Craven, 2003) and mutant mtDNA may be prone to 
producing higher levels of ROS, inducing cellular senescence. The morphology of 
potential senescent cells could be compared to an MCF-7 stock culture that was 
induced into cellular senescence by SN38 at 6 nM with subsequent X-gal staining. 
Senescent positive cells typically exhibit an increased granular appearance and a blue 
precipitate from positive βgalactosidase activity (Langdon 2004). 
 
4.2 Mitochondrial DNA Modification and OXPHOS 
 
4.2.1 The MCF-7 Cancer Cell Line and Mitochondrial Mutation Rate 
 
The MCF-7 cell line mitochondrial DNA deviates from the NCBI sequence NC-
001078 (April 2005) and has the common 73 bp associated with the highly mutagenic 
prostate tumour lines (Chen, 2003). At the very least, a significant subset of human 
tumours experience frequent mutational events within the mtDNA. This is proposed 
to occur as the cell shifts from a benign epithelial cell to a malignant cell, of high 
oxygen consumption particularly in prostate tumours (Costello and Franklin, 2000). 
For this reason, a simple study was conducted with MCF-7 cells grown over an 
extended period to encompass 53 generations. The mitochondrial genes ND1, COI, 
Cytb and the hypervariable D-loop were amplified and sequenced (Chapter 3, Section 
3.4.4). No mutations or mitochondrial heteroplasmy was encountered when compared 
to stock MCF-7 mtDNA. This may suggest a slower mutation rate of human mtDNA 
than estimated by some studies. However, in the present study the cells had gone 
through only 57 generations and only a small number of genes were analysed. 
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4.2.2 MCF-7 Cell Line and Clone Enzyme Activity 
 
One purpose of this thesis was to assess the differences in respiratory chain enzyme 
activity between isolated single cell clones from the MCF-7 stock. Heteroplasmy was 
found in three mitochondrial genes, with different levels of heteroplasmy present in 
clones for the gene Cytb. The enzyme activities of all respiratory complexes were 
measured to determine if there was a correlation between mitochondrial heteroplasmy 
observed and relative enzyme activity (Chapter 3, Table 3.11). These are discussed in 
turn. Figure 4.1 demonstrates the interaction between complexes. The combined 
effects of OXPHOS when one or more complexes have low activity are important in 
the relationship between enzyme activity and PDT. Each enzyme complex of the 
respiratory chain is responsible for supplying substrates to the following complex, 
and/or creating the proton gradient across the inner membrane. 
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Therefore, the presence of one defective enzyme within the respiratory chain may 
impair the overall energy production of OXPHOS. This may occur via the lowered 
production of substrate required by another complex or the decrease in the transport of 
protons across the inner membrane. 
 
4.2.2.1  Complex I- NADH-Coenzyme Q Reductase 
 
 B5 has the lowest complex I activity (PDT 25.5 hours, enzyme activity, 20 µg/sec/mg 
protein), and C12 the highest (PDT, 41 hours, enzyme activity, 82.23 µg/sec/mg 
protein). There appears to be little influence of complex I in relation to PDT in terms 
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Figure 4.1. OXPHOS enzyme activities in relation to function in µg/sec/mg protein. MCF-
7  (PDT 27 hours), B5  (PDT 25.5), C12  (PDT 41), E1  (PDT 28.79), and G8  (PDT 31.76) 
(+SE not shown see Section 3.3.4). This shows relative enzyme activity in relationship with
enzyme function. The  symbol indicates complexes with heteroplasmy in their coding genes. 
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of lowered enzyme activity. Additionally, heteroplamsy was observed within the ND6 
gene in all clones (A14300C at 20% for all clones) producing a stop codon from 
tyrosine. Enzyme activities observed for all clones may be low due to the introduction 
of the stop codon. This resulted in a truncation of the protein by 50 residues. It 
appears the ability of complex I to transport protons across the inner mitochondrial 
membrane may be impaired in the MCF-7 cell line and derivative clone cultures. 
Further, a lowered production of the complex III substrate ubiquinone by complex I 
may also be influential, though complex II also produces this substrate. However, 
clone B5 had low activity for both complex I and II but still had the fasted PDT. The 
differences in activities in complex I in the present research may be due to changes in 
the coding genes of the nuclear DNA. Deficiency in complex I activity has been 
shown to increase the production of superoxide radicals, whilst simultaneously 
inducing superoxide dismutase in human skin fibroblasts (Pitkanen and Robinson, 
1996). Superoxide is a prime character in the initiation of lipid peroxidation (Murphy 
et al., 2003). In the present research, clone B5 PDT does not appear to be impaired, 
despite the potential for greater production of superoxide. A threshold may exist for 
the increased production of superoxide to become deleterious and impair cellular 
respiration. 
 
In a study similar to the aspirations of this thesis, mammalian mitochondrial NADH 
dehydrogenase (complex I) was examined for mitochondrial heteroplasmy in isolated 
murine fibroblasts (Bai et al., 2004). Mutational analysis was carried out on the 
mitochondrial DNA. The mutant cells were selected due to their resistance to rotenone 
(1.2 µM), an inhibitor of complex I (Hofhaus et al., 1995; Bai et al., 2004). Complex I 
functional analysis was achieved by measuring the enzyme activity (capacity) of cells 
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displaying rotenone resistance. An experiment was performed in which a 
heteroplasmy threshold for the ND5 gene was determined. For this, a consistent 
nuclear background was applied by employing a po mitochondrial re-population 
technique. The identified mutation ND5 C12081A is a nonsense mutation resulting in 
truncation of the encoded protein (Bai et al., 2004). Total mRNA level was examined. 
For all except those near mutant homoplasmy the ND5 mRNA level was constant. 
This suggests an independence of the level of heteroplasmy from mRNA transcription 
until a very high threshold is reached. 
 
This thesis found levels of mitochondrial heteroplasmy around 20% (ND6 T14300G 
and Ctyb G15807A) and up to 50% (ATPase6 C9119T). These levels may be below a 
critical threshold to influence mRNA transcription, and hence, protein synthesis. 
Complex I heteroplasmy in single cell clones was 20%. 
 
4.2.2.2  Complex II- Succinate-Coenzyme Q Reductase 
 
Upon comparing enzyme activity to population doubling time, there appears to be 
little influence of the activity of complex II to cell clone population doubling time. As 
clone C12 (PDT 41 hours, 588.84 µg/sec/mg protein) has a higher activity than the 
fastest clone, B5 (PDT 25.5 hours, 148.82 µg/sec/mg protein). Mutation or 
heteroplasmy in the nuclear genes may play a role in the reduced enzyme efficiency 
of the clone B5. 
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4.2.2.3  Complex III- Coenzyme Q-Cytochrome c Reductase 
 
 
There was no detectable activity for the clone C12. This may mean a severe reduction 
in the amount of cytochrome c (II) supplied to complex IV in C12. Complex IV 
activity for C12 is very low also (35.24 µg/sec/mg protein), suggesting the influence 
of a defective complex III protein and/or complex IV protein. There may be other 
factors involved however, as the activity of the MCF-7 stock (3.39 µg/sec/mg protein) 
in supplying reduced cytochrome c to complex IV is not reflected in complex IV 
activity (425 µg/sec/mg protein). MCF-7 displayed G15807A heteroplasmy in the 
Cytb gene at 15%. From mutational analysis, C12 (could not detect enzyme activity) 
did not harbour detectible levels of heteroplasmy in any complex III genes. 
Conversely, G8 also did not display heteroplasmy but had the highest activity (592.15 
µg/sec/mg protein) in complex III. This suggests that the differing activities observed 
for complex III are not due to mitochondrial heteroplasmy, but may be of nuclear 
origin. An additional aspect to consider is that complex III is the site of superoxide 
production (Ramachandran et al., 2002). Hence, high complex III activity may confer 
a disadvantage by producing higher levels of ROS, damaging surrounding proteins. 
 
4.2.2.4  Complex IV- Cytochrome c Oxidase 
 
For complex IV clone G8 did not have detectible activity. Clone C12 had the second 
lowest activity (PDT 41, 35.24 µg/sec/mg protein). Clone B5 had an intermediate 
activity (PDT 25.5, 120.59 µg/sec/mg protein), and the stock culture had the highest 
activity (PDT 27, 425 µg/sec/mg protein). MCF-7 stock had the lowest complex III 
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activity (3.39 µg/sec/mg protein), yet it had the highest complex IV activity. On the 
contrary, clone G8 had the highest complex III activity, yet no detectible complex IV 
activity. Thus, it appears that complex IV activity was not influenced by the amount 
of substrate produced by complex III. Furthermore, a number of human cell types 
have a low in-vivo complex IV capacity (Villani et al., 1998). No mitochondrial 
mutation was detected in the complex IV genes for any of the clones. The lower 
activity of complex IV in clone G8 may be due to mutations in some nuclear encoded 
genes. 
 
 
Complex IV is a key enzyme in OXPHOS in terms of regulation (Bruno et al., 1999; 
Roberts and Pique, 1999, Zhen et al., 1999; DAurelio et al., 2001). Mitochondrial 
encoded subunits I and II form the catalytic centre of the complex (Roberts and Pique, 
1999; Zhen et al., 1999; DAuelio et al., 2001). DAurelio et al. (2001) found a 
correlation between the levels of mutant complex IV encoding mitochondrial DNA, 
mutant mRNA and cell proliferation in cybrid human osteosarcoma 143B cells after 
excluding mitochondria with ethidium bromide. The mutation COX I G6930A results 
in truncation of the protein by 170 residues (Bruno et al., 1999; DAurelio et al., 
2001). COX I DNA and mutant COX I mRNA, were positively correlated, however 
total levels of COX I and mRNA were unchanged (DAurelio et al., 2001). Complex 
IV activity was measured relative to mutation load and was found to decrease 
proportionally. Additionally, the activities of complexes I and III were unchanged in 
mutant complex IV harbouring cells. For complex I and III therefore, there is no 
mutant threshold or indeed compensatory increase, affecting complex activities. 
Growth studies were performed, which demonstrated cells harbouring greater than 
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50% mutant mtDNA were slow to proliferate, and greater than 70% were not able to 
divide (DAurelio et al., 2001). This describes a direct influence of mitochondrial 
heteroplasmy on cell population growth, corroborated by an analogous study (Bruno 
et al., 1999).  
 
In the present research, levels of heteroplasmy present in clone cultures may simply 
be too low to affect cell division and proliferation. A larger sample size is needed to 
determine the heteroplasmy threshold and particular cases of heteroplasmy that are 
influential on growth characteristics. Ideally, a number of different cell lines 
displaying mitochondrial heteroplasmy would be useful in obtaining a broader 
understanding of the influence of heteroplasmy on the respiratory chain in cultured 
human cells. 
 
4.2.2.5  ATP Synthase 
 
ATP synthase was not assayed in this research. Heteroplasmy (G9119A 50%) was 
found in all clone cultures and the MCF-7 stock. There may be an overall effect seen 
in the activity of ATPase in vivo, in which the combined effort of the respiratory chain 
to create the proton gradient between clones may differ. As complexes I, III and IV 
create the proton gradient utilised by ATP synthase, the lowered activities of C12 for 
complexes III and IV responsible for the transfer of protons across the inner 
mitochondrial membrane may result in lowered ATP production (hence, cell 
proliferation) due to a lower ∆Ψm. This may partially account for the longer 
population doubling time for C12. Nuclear mutation may play a significant role also. 
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4.2.3  OXPHOS Substrate Supplementation 
 
Research performed by Folgero et al. (1993) studied the relationship between human 
spermatozoa and OXPHOS substrate supplementation (Folgero et al., 1993). 
Spermatozoa motility was assessed by the swim up method. They found that 12% of 
spermatozoa were motile in media containing 0.5 mM glucose, and an almost three-
fold increase (34%) in motile spermatozoa was observed in a medium containing 0.1 
mM succinate (complex II substrate) and 0.2 mM pyruvate (complex I substrate) in 
addition to glucose. After 20 hours 60% of spermatozoa were motile. Further, control 
subjects (n=2) had higher motility (68%) in the presence of pyruvate, with a detectible 
increase upon the addition of succinate (82%) (Folgero et al., 1993). This study has a 
very small sample size, but is intriguing in regards to sperm motility and 
supplementation of respiratory chain substrate. There is potential for the addition of 
respiratory complex substrates to human cultured cells, which may further elucidate 
the mechanism involved in this study. Thus, if complexes are defective in their ability 
to produce substrate within the respiratory chain, supplementation of required 
biomolecules may show a difference in PDT, demonstrating that the lowered energy 
output was due to substrate deficiency. Conversely, if supplementation does not aid 
proliferation, mitochondrial or nuclear DNA mutation or increased ROS production 
may be influential factors. This could be another means to test the heteroplasmy 
threshold, as addition of exogenous substrate could compensate for a certain level of 
heteroplasmy that may lower protein function thereby supplying the substrate the 
defective protein is unable to produce at physiological levels. For the present research, 
supplementation of ubiquinone and cytochrome c for clones G8 and C12 respectively, 
may elicit a change in complex III and IV activities for these clones.  
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Defects of oxidative phosphorylation can have a negative impact as poor enzyme 
function results in increasing bursts of ROS (Lucas and Szweda, 1998; Chen et al., 
2003). This can have the knock-on effect of increasing mtDNA mutation resulting in 
greater ROS production. This process may well be in action in hyper-mutagenic 
prostate cancer cell lines, resulting in a downward spiral of mutation and superoxide 
production, eliciting more mutation. 
 
 
4.3 Reactive Oxygen Species in Cultured Cells 
 
One of the most common ROS is hydrogen peroxide. It can exist at damaging levels 
in a physiological environment. In addition, it can undergo many reactions producing 
more potent ROS, such as hydroxyl radicals that can elicit DNA damage. 
 
4.3.1  Hydrogen Peroxide and MCF-7 Cells 
 
Hydrogen peroxide has further implications for mitochondria with the induction of 
apoptosis (Miller et al., 2001; Fujii et al., 2002; Behrend et al., 2003), the reduction of 
cellular membrane potential (∆Ψm), DNA fragmentation (Fujii et al., 2002) and 
induction of neoplastic transformation (Arnold et al., 2001; Takabe et al., 2001). 
Addition of H2O2 to human bronchial epithelium cells (transformed by SV-40) at 
levels >200 µM induced a dose-dependant DNA modification. Concentrations of 1 
mM H2O2 resulted in 20% of cell DNA being modified as compared with 5% in the 
control (Fujii et al., 2002). Since the repair mechanism in mitochondria is 
significantly lower than the nuclear base excision and repair system in MCF-7 cells 
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(Croteau et al., 1997; Mambo et al., 2002), any DNA damage induced by AAPH or 
DPPH should be evident without the concern of self-repair in MCF-7 cells (Behrend 
et al., 2003). 
 
4.3.2  Antioxidants in Cell Culture 
 
In the present research AAPH and DPPH were used to treat the MCF-7 cell culture. 
When used in conjunction, the culture experienced a degree of protection from cell 
death as opposed to treatment with AAPH or DPPH alone (Figure 3.29). This may be 
due to a protective effect of DPPH acting as a spin-trap for the carbon centred radicals 
generated from AAPH. Further, there may be a protective effect of membrane 
proteins acting as sacrificial antioxidants due to their abundance in relation to nucleic 
acid. If these sacrificial antioxidants are exhausted there is potential for nucleic acid 
modification by ROS (Genova et al., 2003). The hydroxyl radical, superoxide, 
hydrogen peroxide or lipid peroxides may mediate this directly or indirectly. 
 
4.3.3  Acrolein Involvement in Transformation 
 
Lipid peroxidation has been implicated in male infertility, atherosclerosis and cancer 
(Folgero et al., 1993; Twigg et al., 1998; Aitken and Krausz, 2001; Miller et al., 
2001; Takabe et al., 2001; Holstein et al., 2003). The effects of lipid peroxides 
include DNA damage, alteration of cellular biochemistry (Twigg et al., 1998; Uchida, 
1999; Said et al., 2005) and the production of mutagenic adducts (Takabe et al., 2001). 
A highly mutagenic (and common) lipid peroxidation product is acrolein (Uchida, 
1999; Takebe et al., 2001). 
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 An early event in the exposure of mouse embryo C3H/10T1/2 fibroblast cells was the 
generation of a highly mutagenic lipid peroxidation product, acrolein (Takabe et al., 
2001). The presence of acrolein was observed from the exposure of the culture to 
H2O2 generated indirectly by AAPH. ELISA was used to determine the presence of 
acrolein using a monoclonal antibody raised against acrolein-lysine adducts. Acrolein 
formation was suppressed by the addition of α-tocopherol (supplying a proton for 
abstraction). Takabe et al. (2001) pre-treated C3H/10T1/2 cells with benzo[a]pyrene 
(0.5 µM) before the addition of AAPH (200 µM). The treated fibroblasts underwent 
transformation. It was found that acrolein significantly induced transformation of pre-
treated cells but not the control sample involving 200 µM AAPH alone. This thesis 
research demonstrated the potential induction of transformation with 4mM AAPH 
treatment for 72 hours in MCF-7 cells, without pre-treatment of benzo[a]pyrene 
(Section 3.4.1, Figure 25C). Close to 80% of the cells underwent cell death. The 
surviving fraction was very sluggish, taking 10 days to reach 50% confluence (Figure 
3.37B). There is a notable change in growth habit between the AAPH treated cells  
(Figure 3.37B) and the MCF-7 stock (Figure 3.2E). Figure 3.37A demonstrates the 
morphology of the C12 clone isolated from stock MCF-7. This clone was not treated 
with AAPH or any radical agent, but appears to be a natural sub-population of MCF-7 
that may be more carcinogenic (Zou and Matsumura, 2003).  
 
A possible suggestion for the morphological change after AAPH treatment is the 
production of acrolein, which may be formed in MCF-7 cells upon treatment with 4 
mM AAPH, 2 mM AAPH did not affect the viability of murine fibroblasts (Takabe et 
al., 2001) or the human MCF-7 cell line in the present study. This has bearing on 
many disease states, as ROS, largely lipid peroxidation products, are progenitors of 
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tissue damage and ensuing disease (Aitken and Krausz, 2001; Takabe et al., 2001; 
Khorowbeygi et al., 2004; Sanocka and Kurpisz, 2004). 
 
Despite an 80% reduction in cell number following the AAPH treatment at 4 mM for 
72 hours, no mitochondrial DNA damage was observed in the mitochondrial genes 
sequenced (one third of the mitochondrial genome). This is in contrast to research that 
suggests a correlation between lipid peroxidation, transformation, and the induction of 
DNA damage by mutagenic lipid products in murine fibroblasts (Takabe et al., 2001). 
This may be due to other bio-molecules (for instance sacrificial proteins) being 
oxidised before lipids. Gieseg et al. (2000) found that the peroxidation of proteins 
occurs before lipids in U937 cells (Gieseg et al., 2000). Thus, substantial ROS 
exposure experienced in some diseases may induce mtDNA damage via lipid adducts 
after sacrificial proteins are exhausted (Gil-Guzman et al., 2001). 
 
 
4.3.5  DNA Modification 
 
DNA fragmentation is a pro-mutagenic change that may be the result of oxidative 
stress, abortive Fas-mediated apoptosis or disruption of processes such as 
recombination and chromatin packaging, inducing strand breaks (Aitken and Krausz, 
2001). For the purposes of this thesis the primary focus will be on oxidative stress in 
relation to DNA mutation and cell death.  
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4.3.6  Apoptosis in Free Radical Generator Studies 
   
Apoptosis is commonly referred to as programmed cell death and is a decisive process 
in which a cell initiates a biochemical cascade resulting in cell death (Gieseg et al., 
2000; Chang et al., 2002). Apoptosis can be induced in a number of ways including 
caspase activation and nitric oxide induction, but common to all is the release of 
mitochondrial cytochrome c accompanied by a loss of mitochondrial membrane 
potential (∆Ψm) (Ide et al., 2001; Sanchez-Alcazar et al., 2001; Lachaud et al., 2004). 
 
The free radical generator studies conducted in this thesis explored AAPH and DPPH 
as candidates for inducing mitochondrial DNA mutation. AAPH generates peroxyl 
radicals while DPPH (a stable free radical) is primarily used to test antioxidant 
effectiveness (Kristal et al., 1994; Jin and Chen, 1998; Hussain et al., 2003). Sporadic 
reports have indicated a deleterious oxidant function of DPPH against guinea pig 
cardiac tissue (Jin and Chen, 1998). The findings in the present study were that AAPH 
at 20 mM (1 hour treatment), 2 mM and 4 mM (72 hour treatment) induced cell death. 
Also DPPH at 250 nM (1 hour treatment), and 25 nM (72 hour treatment) induced cell 
death. This AAPH induced cell death was potentially due to apoptosis consistent with 
previous AAPH treatment studies in cell culture (Kristal et al., 1994; Hussain et al., 
2003). In regards to cell proliferation, all levels of AAPH treatment reduced cell 
number leaving a surviving fraction that resulted in a longer lag phase compared to 
the control. Similarly, DPPH treatment at 250 nM resulted in cell death similar in 
morphological change to that of AAPH induced cell death, and resulted in a surviving 
fraction with expectedly longer lag phase. Population doubling times for both AAPH 
and DPPH treated cultures increased by 1 and 0.5 hours, respectively. This confirms a 
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negative impact of both AAPH and DPPH on MCF-7 cell cultures. Thus, lowered 
cellular energy output could be the result of excessive ROS production. This could be 
by endogenous defective respiratory function, or exogenous sources such as defective 
surrounding cells (Gil-Guzman et al., 2001). In the present research, cells that 
underwent free radical generator treatment did not experience mtDNA modification. 
 
4.4 Future Aspirations 
 
An intriguing experiment would be a study on the in organelle foot-printing of MCF-
7 cell mitochondrial DNA, by monitoring the effects of AAPH (or other mutagenic 
agent) on transcription. AAPH may induce mitochondrial DNA mutation in hypotonic 
media (an experiment not conducted in this research), as the pores created on the 
mitochondrial membrane (as mitochondria swell) may be large enough to allow 
AAPH passage. Any induction of mitochondrial mutation or heteroplasmy could 
provide invaluable information by monitoring RNA synthesis. This may differentially 
affect the rates of mRNA and/or rRNA synthesis providing insight into the effect of 
mitochondrial DNA modification on transcription (Vander Heidan et al., 2000; 
Emmerson et al., 2001). The idea stems from the experiment performed by Micol et al. 
(1997), using HeLa cell isolated mitochondria. In their study ethidium bromide and 
ATP were employed to investigate their effect on transcription rate. It was found that 
the intercalating agent ethidium bromide and ATP decreased the rate of rRNA 
synthesis, but not mRNA synthesis.  
 
An additional study will involve the use of a radioactively labelled RNA-synthesizing 
system using intact mitochondria. This could be another means of studying the 
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processing pattern of intact mitochondria harbouring mutant or heteroplasmic DNA. 
By using radioactive label, an in-vivo like processing system can be simulated, 
estimated to be at least 10-15% the in-vivo rate (Gaines and Attardi, 1984). This may 
elucidate the effect of silent mutations on transcription rate and/or processing. 
Messenger RNA transcription of mutant mtDNA is of interest, with a particular focus 
on heteroplasmy and thresholds thereof. As expected, this system is dependant on 
ATP concentration (Gaines and Attardi, 1984; Micol et al., 1997). Much research is 
needed to further elucidate the effect of mitochondrial mutations and mitochondrial 
heteroplasmy on human disease states and ROS production.  
 
4.5 Conclusions 
 
The aspirations of this thesis were to characterize the mammary epithelial cell line 
MCF-7 and assess the relevance natural mitochondrial mutation and OXPHOS 
function in relation to cell proliferation. This was achieved by the isolation of single 
cell, and establishment of genetically homogeneous, clones from the MCF-7 stock and 
characterization of their morphological and proliferate features. Mitochondrial 
mutations were determined by sequencing. Three cases of heteroplasmy were 
identified. One case of heteroplasmy Cytb gene G15807A) was different between 
single cell clones. This mutation did not correlate with population doubling time or 
enzyme activity of the encoded complex III. The effect of free radicals on DNA 
modification and cell proliferation was studied using free radical generators AAPH 
and DPPH. AAPH at 4 mM caused transformation in MCF-7 cells but did not induce 
mitochondrial DNA mutation. DPPH also did not induce mitochondrial DNA 
mutation or transformation in MCF-7 cells consistent with current research. However, 
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AAPH and DPPH did induce cell death that may implicate ROS in the production of 
lipid peroxides and mutagenic adducts facilitating apoptosis. MCF-7 was not found to 
be a hyper-mutagenic cancer cell line, and did not experience mtDNA mutation at the 
rates estimated by some research. Corroboration of these conclusions requires a larger 
sample size of variable single cell clones from MCF-7 and a number of cell lines to be 
investigated in the same manner. Analysis of nuclear coding genes is required to 
determine if variation in enzyme activity stems from nDNA mutation or heteroplasmy, 
or is a result of inadvertent laboratory variation. Furthermore, a number of means to 
estimate respiratory complex function in addition to the biochemical method used in 
this research could be used to eliminate error. In addition, a wider range of 
concentrations of AAPH could be used to treat MCF-7 cells to determine if a process 
of transformation is indeed in place and what concentration of AAPH is required to 
induce it. A study of PDT of treated cells may shed more light of the importance of 
MCF-7 growth habit in determining cell proliferation between potential transformed 
and non-transformed cells. 
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ABBREVIATIONS 
_____________________________________________________________________ 
 
 
AAPH 2,2′-azobis(2-amido 
 propane)dihydrochloride  
APS Ammonium persulphate 
ATCC American type culture   
 collection 
ATP Adenosine triphosphate 
ddH2O Distilled, deionised water 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleoside triphosphate 
ddNTP Dideoxyribonucleoside triphosphate 
DMEM Dulbeccos modified eagles medium 
DMSO Dimethyl sulfoxide 
DPPH 1,1-Diphenyl-2-picryl-hydrazyl 
DTNB 5,5-dithiobis-(2- nitrobenzoate) 
EDTA Ethylenediaminetriacetic acid 
GC Guanosine/Cytosine pairs  
GM Growth medium 
HEPES 4-(2-hydroxyethyl)-1-
 piperazineethanesulfonic acid 
M Molar 
mA Milliamps 
mtDNA Mitochondrial DNA 
NADH Nicotinamide adenine dinucleotide 
nDNA Nuclear DNA 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDT Population doubling time 
ROS Reactive oxygen species 
SNP Single nucleotide polymorphism 
TE8 Tris/EDTA, pH8 
TAE Tris-acetate/EDTA 
Taq Thermus aquaticus 
TBE Tris-borate/EDTA 
TMED N, N, N', N'-Tetramethyl-  
 etheylenediamine 
UV Ultraviolet 
V Volts 
W Watts 
WST-1 (4-[3-(4-Iodophenyl)-2-(4-
nitorphenyl)-2H-5-tetrazolio]-1,3-benzene-
disulfonate) 
w/v Weight per volume 
 
Units: 
g grams 
mg milligrams 
µg micrograms 
 
 
Prefixes: 
c centi (10-2) 
m milli (10-3) 
µ micro (10-6) 
n nano (10-9) 
p pico (10-12) 
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CHEMICAL SUPPLIERS 
____________________________________________________________________
Product    Supplier 
 
 
Acrylamide:bisacrylamide 19:1 BioRad 
(40%) 
 
Agarose    Sigma 
 
Ammonium acetate  BDH 
 
Ammonium persulfate  Boehringer 
    Mannheim 
 
Ascorbate   Sigma 
 
2,2′-azobis(2-amido propane) 
dihydrochloride (AAPH)  Sigma 
 
Bovine serum albumin V  Boehringer 
    Mannheim 
 
Bromophenol blue  Sigma 
 
Chlofoform   BDH 
 
Deoxynucleoside  
triphosphates (dNTPs)  Eppendorf 
 
Dimethyl sulfoxide (DMSO) Gibco 
    (Invitrogen) 
 
1,1-Diphenyl-2-picryl-hydrazyl Sigma 
(DPPH) 
 
5,5-dithiobis-(2- nitrobenzoate) 
(DTNB)    Sigma 
 
1, 4-Dithiothreitol (DTT)  Boeringer 
    Mannheim 
Dulbeccos modified  
eagles media (DMEM)  Gibco   
    (Invitrogen) 
 
Ethanol    BDH  
 
Ethidium bromide  Sigma 
 
Ethylene diaminetetra  
acetic acid (EDTA)  BDH 
 
Foetal bovine sera  Gibco  
     
Hepes    Boehringer 
    Mannheim 
Product   Supplier 
  
 
Isoamyl alcohol  BDH 
 
Isopropanol  BDH 
 
Mineral oil  Sigma 
 
Nicotinamide adenine  
dinucleotide (NADH) Sigma 
  
Orange G  Sigma 
 
Oxaloacetate  Sigma 
 
Penicillin/  Gibco 
Streptomycin  (Invitrogen) 
 
Phenol   Scharlau  
  (Scientific Supplies Ltd) 
 
Potassium cyanide Sigma  
 
Proteinase K  Roche  
 
Sephadex G-25  Amersham 
 
Sephadex G-50  Amersham 
 
Sodium acetate  BDH 
 
Sodium borohydride Sigma 
 
Sodium chloride  BDH  
   
Sodium dodecyl sulfate  
(SDS)   Gibco (Invitrogen) 
 
Sodium hydroxide BDH   
 
N,N,N,N-Tetramethyl- Sigma 
ethylelediamine (TMED) 
 
Taq   Roche 
 
Tris base  Boehringer  
   Mannheim 
 
Ubiquinone  Sigma 
 
Urea   BDH 
 
Xylene cyanol  Sigma 
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PCR AND SEQUENCING 
_____________________________________________________________________ 
 
 
 
Figure 1A. DNA spotting to visualise relative quantities of isolated DNA compared to a 
known quantity of λ DNA. A, a, λ 0.1 µg; b, λ 0.01 µg; c, MCF-7; d, G8; e, C12; f, B5; g, E1; h, 
AAPH treated cell culture DNA. B, a, λ 0.1 µg; b, λ 0.06 µg; c, λ 0.04 µg;  d, λ 0.02 µg; e, λ 0.01 
µg;  f, C12; g, B5; h, MCF-7; i, E1;  j, DPPH treated cell culture DNA k, G8. 
 
 
 
 
 
Figure 1. A, PCR product from the D-loop gene for radical treated cell culture DNA. Lane 1, 
molecular marker λHindIII/EcoRI; lane 2 and 3, MCF-7 continuous growth DNA; lane 4 and 5, 2 
mM AAPH treated cell culture DNA; lane 6 and 7, 25 nM DPPH treated cell culture DNA; lane 8 
and 9, AAPH and DPPH treated cell culture DNA; lane 10, negative control. B, PCR product 
from the COII gene for radical treated cell culture DNA. Lane 1, molecular marker 
λHindIII/EcoRI; lane 2 and 3, MCF-7 continuous growth DNA; lane 4 and 5, 2 mM AAPH 
treated cell culture DNA; lane 6 and 7, 25 nM DPPH treated cell culture DNA; lane 8 and 9, 
AAPH and DPPH treated cell culture DNA; lane 10, negative control. 
 
 
 
 
 
 
Figure 2. A, PCR precipitate of the ND1 gene for free radical treated cell cultures. 
Lane 1, molecular marker λHindIII/EcoRI; lane 2 and 3, MCF-7 continuous growth 
DNA; lane 4 and 5, 2 mM AAPH treated cell culture DNA; lane 6 and 7, 25 nM 
DPPH treated cell culture DNA; lane 8 and 9, AAPH and DPPH treated cell culture 
DNA. B, PCR precipitate 
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Figure 3. PCR of mitochondrial genes with MCF-7 DNA from cell 
culture treated with AAPH 20 mM for 1 hour. Lane 1, molecular 
marker λHindIII/EcoRI; ane 3 and 3, Cytb gene product; lane 4 and 5, 
D-loop gene product; lane 6 and 7, COI gene product; lane 8 and 9, 
ND1 gene product; lanes 10 to 12, negative controls 
 
 
 
Figure 4. A. B. PCR product of the ATPase gene for MCF-7. Lane 1, 
molecular marker λHindIII/EcoRI; lane 2 to 7, ATPase product; lane 8, 
negative control.  
 
 
 
Figure 5. A, PCR product for the ND6 gene. Lane 1, molecular marker λHindIII/EcoRI; 
lane 2 to 6, ND6 gene product; lane 7, negative control.    
 
 
 
 
 Figure 6. A, PCR product for the COI gene for MCF-7. Lane 1, molecular marker 
λHindIII/EcoRI; lane 2 to 5, MCF-7; lane 6, negative control. B, PCR product for 
mitochondrial genes for MCF-7. Lane 1, molecular marker λHindIII/EcoRI; lane 2 to 
5, PCR product of the COI gene; lane 6, negative control; lane 7 to 10, PCR product 
of the COIII gene; lane 11, negative control. 
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Figure 7. A, PCR product from the 12S gene. Lane 1, molecular marker λHindIII/EcoRI, lane 
2 and 3, G8 clone; lane 4 and 5, E1 clone; lane 6 and 7, B5 clone, lane 8 and 9, C12 clone, lane 
10, negative control. B, PCR products of mitochondrial genes for C12 clone. Lane 1, 
molecular marker λHindIII/EcoRI; lane 2 and 3, COIII gene; lane 4 and 5, COI gene; lane 6 
and 7, ATPase gene; lane 8 and 9, ND6 gene; lane 9, negative control for ND6. Other controls 
had no banding (not shown). 
 
 
 
 
 
Figure 8. PCR product for MCF-7. A, Lane 1, molecular marker λHindIII/EcoRI; lane 2 to 5, 
product for the COI gene; lane 6 to 9, product for the COIII gene; lane 10 and 11, negative controls. 
B, PCR product for mitochondrial genes for MCF-7. Lane 1, molecular marker λHindIII/EcoRI; 
lane 2 to 5, product for the ATPase gene; lane 6, negative control for ATPase; lane 7 to 10, product 
for the ND6 gene; lane 11, negative control for ND6. 
 
 
 
 
 
Figure 9. A, PCR products of mitochondrial genes for G8 clone. Lane 1, molecular marker 
λHindIII/EcoRI; lane 2 and 3, COIII gene; lane 4 and 5, COI gene; lane 6 and 7, ATPase gene; 
lane 8 and 9, ND6 gene; lane 10 to 14  negative controls. B, PCR product for the ND4 gene. 
Lane 1, molecular marker λHindIII/EcoRI; lane 2 and 3, G8 clone; lane 4 and 5, C12 clone; lane 
6 and 7, E1 clone; lane 8 and 9, B5 clone; lane 10, negative control. 
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Figure 10. A. PCR precipitate of the ATPase gene. Lane 1, molecular marker 
λHindIII/EcoRI; lane 2 to 7, ATPase precipitate. B. PCR product for the ATPase 
gene. Lane 1, molecular marker λHindIII/EcoRI; lane 2 to 6, ND6 gene product; 
lane 7, negative control.    
 
 
 
 
 
Figure 11. A, PCR precipitate of mitochondrial gene products form MCF-7 DNA from cell 
culture treated with 20 mM AAPH for 1 hour. Lane 1, molecular marker λHindIII/EcoRI; lane 2 
and 3, Cytb gene product; lane 4 and 5, D-loop gene product; lane 6 and 7, COI gene product; lane 
8 and 9, ND1 gene product; lanes 10 to 12, negative controls. B, PCR precipitate from 
mitochondrial gene products. Lane 1, molecular marker λHindIII/EcoRI; lane 2 and 3, E1 clone 
product for 12S; lane 4 and 5, E1 clone product for ND2; lane 6 and 7, MCF-7 product for ND2; 
lane 8 and 9, G8 clone product for ND2; lane 10 and 11, B5 clone product for ND2; lane 12, C12 
clone product for ND2. (Negative controls not pictured). 
 
 
 
 
 
Figure 12. A, PCR product for the COII gene. Lane 1, molecular marker λHindIII/EcoRI; lane 2 
and 3, MCF-7; lane 4 and 5, clone E1; lane 6 and 7, clone G8; lane 8 and 9, clone C12; lane 10 
and 11, clone B5; lane 12, negative control. B, PCR precipitate of the COII gene for continuous 
radical treated cells. Lane 1, molecular marker λHindIII/EcoRI; lane 2 and 3, MCF-7; lane 4 and 
5, clone E1; lane 6 and 7, clone G8; lane 8 and 9, clone C12; lane 10 and 11, clone B5; lane 12, 
negative control. 
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Figure 13. PCR precipitate for the COIII gene. Lane 1, molecular 
marker λHindIII/EcoRI; lane 2 and 3, MCF-7; lane 4 and 5, clone 
E1; lane 6 and 7, clone G8; lane 8 and 9, clone C12; lane 10 and 
11, clone B5; lane 12, negative control. 
 
 
 
        
Figure 14. ABI Chromatographs of the ATPase gene (reverse sequence shown) displaying C→T 
base heteroplasmy. A, C12. B, G8. 
 
 
     
Figure 15. ABI Chromatographs of the ND6 gene. (forward sequence shown) displaying T→G 
heteroplasmy. A, C12. B, B5. 
 
 
    
       
Figure 16. ABI Chromatographs of the ND6 gene. (forward sequence shown) displaying T→G 
heteroplasmy. A, E1. B, G8. 
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Figure 17. ABI Chromatographs of the ND6 gene. (forward sequence shown) displaying T→G 
heteroplasmy. A, MCF-7 B, E1. 
 
 
 
Figure 18. ABI Chromatograph of a portion of the ND2 gene from MCF-7 (reverse sequence 
shown). 
 
 
 
Figure 19. ABI Chromatograph from a portion of the ND2 gene of MCF-7 (forward sequence 
shown). 
 
 
 
Figure 20. ABI Chromatograph of a portion of the 16S gene of MCF-7 (forward sequence shown). 
 
 
 
Figure 21. ABI Chromatograph of a portion of the 16S gene of MCF-7 (forward sequence shown). 
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Figure 22. ABI Chromatograph of a portion of the ND4 gene of MCF-7 (forward sequence shown). 
 
 
 
Figure 23. ABI Chromatograph of a portion of the ND4 gene of MCF-7 (reverse sequence shown). 
 
 
 
Figure 24. ABI Chromatograph of a portion of the COI gene of MCF-7 (forward sequence shown). 
 
 
 
Figure 25. ABI Chromatograph of a portion of the COIII gene of MCF-7 (forward sequence 
shown). 
 
 
 
Figure 26. ABI Chromatograph of a portion of the ND1 gene of MCF-7 (forward sequence shown). 
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Figure 27. ABI Chromatograph of a portion of the D-loop gene of MCF-7 (forward sequence 
shown). 
 
 
 
Figure 28. ABI Chromatograph of a portion of the ND5 gene of MCF-7 (forward sequence shown). 
 
 
 
References 
 103
REFERENCES 
________________________________________________________________________________ 
 
Aggeler, R., Coons, J., Taylor, S., Ghosh, S., Garcia, J., Capaldi, R., Marusich, M. (2002). "A 
functionally active human F1F0 ATPase can be purified by immunocapture from heart 
tissue and fibroblast cell lines." J. Biol. Chem. 277(37): 33906-33912. 
 
Aitken, R., Krausz, C. 2001. Oxidative stress, DNA damage and the Y chromosome. Reprod. 122: 
497-506. 
  
Aitken, R., Fisher, H., Fulton, N., Gomez, E., Knox, W., Lewis, B., Irvine, S. (1997). "Reactive 
oxygen species generation by human spermatozoa is induced by exogenous NADPH and 
inhibited by the flavoprotein inhibitors diphenylene iodonium and quinacrine." Mol. 
Reprod. Dev. 47: 468-482. 
  
Allen, R., Keogh, B., Tresini, M., Gerhard, G., Volker, C., Pignolo, R., Horton, J., Cristofalo, V. 
(1997). "Development and age-associated differences in electron transport potential and 
consequences for oxidant generation." J. Biol. Chem. 272(40): 24805-24812. 
  
Anderson, S, Bankier, A., Barrell, B., de Bruijin D., Colson, A., Drouin J, Eperon, I., Nierlich DP, 
Roe BA, Sanger F, Schreier PH, Smith, A., Staden, R., Young IG. (1981). Sequence and 
organization of the human mitochondrial genome. Nature. 290(5806): 457-65 
  
Arnold, R., Shi, J., Murad, E., Whalen, A., Sun, C., Polavarapu, R., Parthasarathy, S., Petros, J., 
Lambeth, J. (2001). "Hydrogen peroxide mediates the cell growth and transformation 
caused by the mitogenic oxidase Nox1." PNAS 98(10). 
  
Bai, Y., Hu, P., Park, J., Deng, J., Song, X., Chomyn, A., Yagi, T., Attardi, G. (2004). "Genetic and 
functional analysis of mitochondrial DNA-encoded complex I genes." Ann. N. Y. Acad. Sci. 
1011: 272-283. 
  
Ballard, J., Whitlock, M. (2004). "The incomplete natural history of mitochondria." Mol. Ecol. 13: 
729-744. 
  
Barrientos, A. (2002). "In vivo and in organello assessment of OXPHOS activities." Methods 26: 
307-316. 
  
Battersby, B., Loredo-Osti, J., Shoubridge, E. (2003). "Nuclear genetic control of mitochondrial 
DNA segregation." Nat. Genet. 33(2): 183-186. 
  
Behrend, L., Henderson, G., Zwacka, R. (2003). "Reactive oxygen species in oncogenic 
transformation." Biochem. Soc. Trans. 31(6): 1441-1444. 
  
Birch-Machin, M., Briggs, H./, Saborido, A., Bindoff, L., Turnbull, D. (1994). "An evaluation of 
the measurerment of the activities of complexes I-IV in the respiratory chain of human 
skeletal muscle mitochondria." Biochem. Med. Metab. 51: 35-42. 
  
Bourges, I., Ramus, C., Mousson de Camaret, B., Beugnot, R., Remacle, C., Cardol, P., Hofhaus, 
G., Issartel, J. (2004). "Structural organization of mitochondrial human complex I: role of 
References 
 104
the ND4 and ND5 mitochondria-encoded subunits and interaction with prohibitin." 
Biochem. J. 383: 491-499. 
  
Bradford, M. (1976). "A rapid and sensitive method for the quantification of microgram quantities 
of protein utilizing the principle of protein-dye binding." Anal. Biochem. 7(72): 248-254. 
  
Brown, W., George, M., Wilson, A. (1979). "Rapid evolution of animal mitochondrial DNA`." 
Proc. Natl. Acad. Sci. 76(4): 1967-1971. 
  
Bruno, C., Martinuzzi, A., Tang, Y., Andreu, A., Pallotti, F., Bonilla, E., Shanske, S., Fu, J., Sue, 
C., Angelini, C., DiMauro, S., Manfredi, G. (1999). "A stop-codon mutation in the human 
mtDNA cytochrome c oxidase I gene disrupts the functional structure of complex IV." Am. 
J. Hum. Genet. 65: 611-620. 
  
Cavelier, L., Johannisson, A., Gyllensten, U. (2000). "Analysis of mtDNA copy number and 
composition of single mitochondrial particles using flow cytometry and PCR." Exp. Cell. 
Res. 259: 79-85. 
  
Chang, W., Lui, J., Chen, C., Huang, T., Lu, F. (2002). "Growth inhibition and induction of 
apoptosis in MCF-7 breast cancer cells by fermented soy product." Nutrition and Cancer 
43(2): 214-226. 
  
Chen, J., Gokden, N., Greene, G. (2003). "Simultaneous generation of multiple mitochondrial DNA 
mutations in human prostate tumours suggests mitochondrial hyper-mutagenesis." 
Carcinogenesis 24(9): 1481-1487. 
  
Chomyn, A., Enriquez, J., Micol, V., Fernandez-Silva, P., Attardi, G. (2000). "The mitochondrial 
myopathy, encephalopathy, lactic acidosis, and stroke-like episode syndrome-associated 
human mitochondrial tRNALEU(UUR) mutation causes aminoacylation deficiency and 
concomitant reduced association of mRNA with ribosomes." J. Biol. Chem. 275(25): 
19198-19209. 
  
Cortopassi, G., Shibata, D., Soong, N., Arnheim, N. (1992). "A pattern of accumulation of a 
somatic deletion of mitochondrial DNA in aging human tissues." Proc. Natl. Acad. 89: 
7370-7374. 
 
Costello, L., Franklin, R. (2000). The intermediary metabolism of the prostate: a key to 
understanding the pathogenesis and progression of malignancy Oncology. 59: 269-282. 
  
Croteau, D., Bohr, V. (1997). "Repair of oxidative damage to nuclear and mitochondrial DNA in 
mammalian cells." J. Biol. Chem. 272(41): 25409-25412. 
  
Cummins, J., Jequier, A., Kan, R. (1994). "Molecular biology of human male infertility: links with 
aging, mitochondrial genetics, and oxidative stress?" Mol. Reprod. Dev. 37: 345-362. 
   
D'Aurelio, M., Pallotti, F., Barrientos, A., Gajewski, C., Kwong, J., Bruno, C., Beal, M., Manfredi, 
G. (2001). "In vivo regulation of oxidative phosphorylation in cells harbouring a stop-codon 
mutation in mitochondrial DNA-encoded cytochrome c oxidase subunit I." J. Biol. Chem. 
276(50): 46925-46932. 
  
References 
 105
Devarajan, E., Chen, J., Multani, A. (2002). "Human breast cancer MCF-7 cell line contains 
inherently drug-resistant subclones with distinct genotypic and phenotypic features." Inter. 
Jour. Oncology. 20: 913-920. 
 
de Lamirande, E., Harakat, A. Gagnon, C. 1998. Human sperm capacitation induced by biological 
fluids and progesterone, but not by NADH or NADPH, is associated with the production of 
superoxide anion. J. Androl. 19(2): 215-225. 
  
Diaz, F., Bayona-Bafaluy, M., Rana, M., Mora, M., Hao, H., Moraes, C. (2002). "Human 
mitochondrial DNA with large deletions repopulates organelles faster that full-length 
genomes under relaxed copy number control." Nucl. Acid. Res. 30(21): 4626-4633. 
  
Diekert, K., de Kroon, A., Kispal, G., Lill, R. (2001). "Isolation and subfractionation of 
mitochondria from the yeast Saccharomyces cerevisiae." Meth. Cell. Biol. 65: 37-49. 
  
Diez-Sanchez, C., Ruiz-Pesini, E., Montoya, J., Perez-Martos, A., Enriquez, J. A., Lopez-Perez, M. 
J. (2003). "Mitochondria from ejaculated human spermatozoa do not synthesize proteins." 
FEBS Letters 553: 205-208. 
  
DiMauro, S., Andreu, A. (2000). "Mutations in mtDNA: are we scraping the bottom of the barrel?" 
Brain Pathology 10: 431-441. 
  
DiMauro, S., Schon, E. (2001). "Mitochondrial DNA mutation in human disease." Am. J. Med. 
Genet. 106: 18-26. 
   
Emmerson, C., Brown, G., Puolton, J. (2001). "Synthesis of mitochondrial DNA in permeabilised 
human cultured cells." Nucl. Acid. Res. 29(2): 1-9. 
  
Enriquez, J., Cabezas-Herrera, J., Bayona-Bafaluy, M., Attardi, G. (2000). "Very rare 
complementation between mitochondria carrying different mitochondrial DNA mutations 
points to intrinsic genetic autonomy of the organelles in cultured human cells." J. Biol. 
Chem. 275(15): 11207-11215. 
  
Felty, Q., Roy, D. (2005). "Estrogen, mitochondria, and growth of cancer and non-cancer cells." 
Jour. Carcin. 4(1): 1-18. 
  
Folgero, T., Bertheussen, K.,  Lindal, S., Torbergsen, T., Oian, P. (1993). "Mitochondrial disease 
and reduced sperm motility." Human. Reprod. 8(11): 1863-1868. 
  
Freshney, I. (2000). "Culture of animal cells, forth edition." Wiley-Liss, Inc Canada. 
  
 
Fujii, Y., Tomita, K., Sano, H. Yamasaki, A., Hitsuda, Y., Adcock, I., Shimizu, E. (2002). 
"Dissociation of DNA damage and mitochondrial injury caused by hydrogen peroxide in 
SV-40 transformed lung epithelial cells." Can. Cell. Inter. 2(16). 
  
Gaines, G., Attardi, G. (1984). "Highly efficient RNA-synthesizing system that uses isolated 
human mitochondria: new initiation events and in vivo-like processing patterns." Mol. Cell. 
Biol. 4(8): 1605-1617. 
  
References 
 106
Garrett, R., Grisham, C. (1999). "Biochemistry second edition." Saunders College Publishing, USA. 
  
GenomeNet, B. c., Institute for chemical research, Kyoto university. http://www.genomenet.jp 
(2004). 
  
Genova, M. L., Pich, M. M., Biondi, A. (2003). "Mitochondrial production of oxygen radical 
species and the role of coenzyme Q as an antioxidant." Exp. Biol. Med. 228: 506-513. 
  
Gieseg, S., Duggan, S., Gebicki, J. (2000). "Peroxidation of proteins before lipids in U937 cells 
exposed to peroxyl radicals." Biochem. J. 350: 215-218. 
  
Gieseg, S., Pearson, J., Firth, C. (2003). "Protein hydroperoxides are a major product of low density 
lipoprotein oxidation during copper, peroxyl radical and macrophage-mediated oxidation." 
Free Rad. Research. 37(9): 983-991. 
  
Gil-Guzman, E., Ollero, M., Lopez, M., Sharma, R., Alvarez, J., Thomas, A., Agarwal, A. (2001). 
"Differential production of reactive oxygen species by subsets of human spermatozoa at 
different stages of maturation." Hum. Reprod. 16(9): 1922-1930. 
  
Grzybowski, T. (2000). "Extremely high levels of human mitochondrial DNA heteroplasmy in 
single hair roots." Electrophoresis 21: 548-553. 
 
Halliwell, B., Gutteridge, J. (1999). Free radicals biology and medicine. Clarendon Press, 
Oxford, England. 
  
Hand, R., Craven, R. (2003). "Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 
human breast cancer cells." Jour. Cell. Biochem. 90: 534-547. 
   
Hofhaus, G., Johns, D., Hurko, O., Attardi, G., Chomyn, A. (1996). "Respiration and growth 
defects in transmitochondrial cell lines carrying the 11778 mutation associated with Leber's 
hereditary optic neuropathy." J. Biol. Chem. 271(22): 13155-13161. 
  
Hofhaus, G. A., G. (1993). "Lack of assembly of mitochondrial DNA-encoded subunits of 
respiratory NADH dehydrogenase and loss of enzyme activity in a human cell mutant 
lacking the mitochondrial ND4 gene product." EMBO J. 12: 3043-3048. 
  
Hofhaus, G. A., G. (1995). "Efficient selection and characterization of mutants of a human cell line 
which are defective in mitochondrial DNA-encoded subunits of respiratory NADH 
dehydrogenase." Mol. Cell. Biol. 15(2): 964-974. 
   
Holstein, A., Schulze, W., Davidoff, M. (2003). "Understanding spermatogenesis is a prerequisite 
for treatment." Reprod. Biol. Endo. 107(1). 
  
Holt, I., Harding, A., Morgan-Hughes, J. (1989). "Deletions of muscle mitochondrial DNA in 
mitochondrial myopathies: sequence analysis and possible mechanisms." Nucl. Acid. Res. 
17(12): 4465-4469. 
   
Hussain, S. P., Hofseth, l. J., Harris, C. C. (2003). "Radical causes of cancer." Nature reviews 3: 
276-285. 
  
References 
 107
Ide, T., Tsutsui, H., Hayashidani, S. (2001). "Mitochondrial DNA damage and dysfunction 
associated with oxidative stress in failing hearts after myocardial infarction." Circ. Res. 88: 
529-535. 
  
Jacobs, H. (2003). "Disorders of mitochondrial protein synthesis." Hum. Mol. Genet. 12(2): 293-
301. 
  
Jin, Z. Q., Chen, X. (1998). "A simple reproducible model of free radical-injured isolated heart 
induced by 1,1-diphenyl-2-picryl-hydrazyl (DPPH)." Jour. of Pharm. and Toxic. Meth. 39: 
63-70. 
  
Khosrowbeygi, A., Zarghami, N., Deldar, Y. (2004). "Correlation between sperm quality 
parameters and seminal plasma antioxidant status." Iran. J. Reprod. Med. 2(2): 58-64. 
  
King, M. P., Attardi, G. (1989). "Human cells lacking mtDNA: repopulatiopn with exogenous 
mitochondria by complementation." Science 246: 500-503. 
  
Kirino, Y., Yasukawa, T., Ohta, S., Akira, S., Ishihara, K., Watanabe, K., Suzuki, T. (2004). 
"Codon-specific translational defect caused by a wobble modification deficiency in mutant 
tRNA from a human mitochondrial disease." PNAS 101(42): 15070-15075. 
  
Kirino, Y., goto, Y., Campos, Y., Arenas, J., Suzuki, T. (2005). "Specific correlation between the 
wobble modification deficiency in mutant tRNAs and the clinical features of a human 
mitochondrial disease." PNAS 102(20): 7127-7132. 
  
Kirstal, B., Chen, J., Pal Yu, B. (1994). "Sensitivity of mitochondrial transcription to different 
radical species." Free Rad. Biol. Med. 16(3): 323-329. 
  
Klug, W., Cummings, M (1997). "Concepts of genetics." Prentice Hall New Jersey. 
  
Lachaud, C., Tesarik, J., Canadas, M., Mendoza, C. (2004). "Apoptosis and necrosis in human 
ejaculated spermatozoa." Hum. Reprod. 19(3): 607-610. 
  
Lacroix, M., Leclercq, G. (2004). "Relevance of breast cancer cell lines as models for breast 
tumours: an update." Breast cancer reaserch and treatment 83(3): 249-289. 
  
Langdon, S. (2004). "Cancer cell culture." Humana Press, NJ, USA. 
  
Larsson, N. G., Oldfors, A., Garman, J. D., Barsh, G. S., Clayton, D. A. (1997). "Down-regulation 
of mitochondrial transcription factor A during spermatogenesis in humans." Hum. Mol. 
Genet. 6(2): 185-91. 
  
Lucas, D., Szweda, L. (1998). "Cardiac reperfusion injury: aging, lipid peroxidation, and 
mitochondrial dysfunction." Proc. Natl. Acad. Sci. 95: 510-514. 
  
Mambo, E., Nyaga, S., Bohr, V., Evans, M. (2002). "Defective repair of 8-hydroxyguanine in 
mitochondria of MCF-7 and MDA-MB-468 human breast cancer cell lines." Cancer 
Research 62: 1349-1355. 
  
References 
 108
Max, B. (1992). This and that: hair pigments, the hypoxic basis of life and the Virgilian journey of 
the spermatozoon. Trends Pharmacol. Sci., 13, 272-276. 
 
 
May-Panloup, P. M., Cheretein, M. F., Savagner, F., Vasseur, C., Jean, M., Malthiery, Y., Reynier, 
P. (2003). "Increased sperm mitochondrial DNA content in male infertility." Hum. Reprod. 
18(3): 550-556. 
  
Micol, V., Fernandez-Silva, P., Attardi, G. (1997). "Functional analysis of in vivo and in organello 
footprinting of HeLa cel mitochondrial DNA in relationship to ATP and ethidium bromide 
effects on transcription." J. Biol. Chem. 272(30): 18896-18904. 
  
Miller, M., Angeles, F., Reuter, B., Bobrowski, P., Sandoval, M. (2001). "Dietary antioxidants 
protect gut epithelial cells from oxidant-induced apoptosis." BMC 1(11). 
  
MITOMAP. A human mitochondrial genome database, www.mitomap.org. (2005). 
  
Moustafa, M., Sharma, R., Thornton, J., Mascha, E., Abdel-Hafez, M., Thomas, A., Agarwal, A. 
(2004). "Relationship between ROS production, apoptosis and DNA denaturation in 
spermatozoa from patients examined for infertility." Hum. Reprod. 19(1): 129-138. 
  
Murphy, M., Echtay, K., Blaikie, F., Asin-Cayuela, J., Cocheme, H., Green, K., Buckingham, J., 
Taylor, E., Hurrell, F., Hughes, G., Miwa, S., Cooper, C., Svistunenko, D., Smith, R., 
Brand, M. (2003). "Superoxide activates uncoupling proteins by generating carbon-centred 
radicals and initiating lipid peroxidation." Jour. Biol. Chem. 278(49): 48534-48545. 
  
Pitkanen, S., Robinson, B. (1996). "Mitochondrial complex I deficiency leads to increased 
production of superoxide radicals and induction of superoxide dismutase." J. Clin. Invest. 
98(2): 345-351. 
  
Quintana-Murci, L., Rotig, A., Munnich, A., Rustin, P., Bourgeron, T. (2001). "Mitochondrial 
DNA inheritance in patients with deleted mtDNA." J. Med. Genet. 38(28). 
  
Ramachandran, A., Moellering, D., Ceaser, E. (2002). "Inhibition of mitochondrial protein 
synthesis results in increased endothelial cell susceptibility to nitric oxide-induced 
apoptosis." PNAS 99(10): 6643-6648. 
  
Rantanen, A., Jansson, M., Oldfors, A., Larsson, N. (2001). "Downregulation of Tfam and mtDNA 
copy number during mammalian spermatogenesis." Mamm. Genome. 12(10): 787-792. 
  
Richer, S., Ford, W. (2001). "A critical investigation of NADPH oxidase activity in human 
spermatozoa." Mol. Hum. Reprod. 7(3): 237-244. 
  
Roberts, V., Pique, M. (1999). "Definition of the interaction domain for cytochrome c on 
cytochrome c oxidase." J. Biol. Chem. 274(53): 38051-38060. 
  
Ross, J. (2004). " www.jdaross.mcmail.com." 
  
Rossingnol, R., Letellier, T., Malgat, M. (2000). "Tissue variation in the control of oxidative 
phosphorylation: implication for mitochondrial diseases." Biochem. J. 347: 45-53. 
References 
 109
  
Ruiz-Pesini, E., Diez, C., Lapena, A. C., (1998). "Correlation of sperm motility with mitochondrial 
enzyme activities." Clin. Chem. 44(8): 1616-1620. 
  
Ruiz-Pesini, E., Lapena, A., Diez-sanchez, C., Perez-martos, A., Montoya, J., Alvarez, E., Diaz, 
M., Urries, A., Montoro, L., Lopez-perez, M., Enriquez, J. (2000b). "Human mtDNA 
haplogroups associated with high or reduced spermatozoa motility." Am. J. Hum. Genet. 67: 
682-696. 
  
Ruiz-Pesini, E., Lapena, A., Diez, C., Alvarez, E., Enriquez, J., Lopez-Perez, M. (2000a). "Seminal 
quality correlates with mitochondrial functionality." Clin. Chim. Acta. 300: 97-105. 
  
Rustin, P., Parfait, B., Chretien, D., Bourgeron, T., Djouadi, F., Bastin, J., Rotig, A., Munnich, A. 
(1996). "Fluxes in nicotinamide adenine dinucleotides through mitochondrial membranes in 
human cultured cells." Jour. Biol. Chem. 271(25): 14785-14790. 
  
Said, T., Agarwal, A., Sharma, R., Thomas, A., Sikka, S. (2005). "Impact of sperm morphology on 
DNA damage caused by oxidative stress induced by beta-nicotinamide adenine dinucleotide 
phosphate." Fertility and Sterility 83(1): 95-103. 
  
Sanchez-Alcazar, J., Khodjakov, A., Schneider, E. (2001). "Anticancer drugs induce increased 
mitochondrial cytochrome c expression that precedes cell death." Cancer Research 61: 
1038-1044. 
  
Sanocka, D., Kurpisz, M. (2004). "Reactive oxygen species and sperm cells." Reprod. Biol. Endo. 
2(12). 
  
Shoubridge, E. A. (2001). "Nuclear genetic defects of oxidative phosphorylation." Human Mol. 
Gen. 10(20): 2277-2284. 
  
Siguroardottir, S., Helgason, A., Gulcher, J. R., Stefansson, K., Donnelly, P. (2000). "The mutation 
rate in the human mtDNA control region." Am. J. Hum. Genet. 66: 1599-1609. 
  
Simandan, T., Sun, J., Dix, T. (1998). "Oxidation of DNA bases, deoxyribonucleosides and 
homoploymers by peroxyl radicals." Biochem. J. 335: 233-240. 
  
Smith, C. (2004). "ATPases: diverse roles and common themes." NZ Bioscience: 32-36. 
  
Snustad, D., Simmons, M. (1997). "Principles of Genetics, second edition, John Wiley and Sons 
New York. 
  
Sottocasa, G. L., Kuylenstierna, B., Ernster, L. (1967). "An electron-transport system associated 
with the outer membrane of liver mitochondria." Jour. Cell. Biol. 32: 415-438. 
  
Srere, P. (1960). "Citrate Synthase." Meth. Enzym. 11: 3-11. 
  
St John, J. C., Jokhi, R. P., Barratt, C. L. R. (2001). "Men with oligoasthenoteratozoospermia 
harbour higher numbers of multiple mitochondrial DNA deletions in their spermatozoa, but 
individual deletions are not indicative of overall aetiology." Mol. Hum. Reprod. 7(1): 103-
111. 
References 
 110
  
Sutherland, R., Hall, R., Taylor, I. (1983). "Cell proliferation kinetics of MCF-7 human mammary 
carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-
phase cells." Cancer Research 43: 3998-4006. 
  
Suzuki, T., Suzuki, T., Wada, T., Saigo, K., Watanabe, K. (2002). "Taurine as a constituent of 
mitochondrial tRNAs: new insights into the functions of taurine and human mitochondrial 
diseases." The EMBO J. 21(23): 6581-6589. 
  
Takabe, W., Niki, E., Uchida, K. (2001). "Oxidative stress promotes the development of 
transformation: involvement of a potent mutagenic lipid peroxidation product, acrolein." 
Carcinogenesis 22(6): 935-941. 
  
Taylor, I., Hodson, P., Green, M., Sutherland, R. (1983). "Effects of tamoxifen on cell cycle 
progression of synchronous MCF-7 human mammary carcinoma cells." Cancer Research 
43: 4007-4010. 
  
Taylor, W., Taylor, G., Durham, S., Turnbull, D. (2001). "The determination of complete human 
mitochondrial DNA sequences in single cells: implications for the study of somatic 
mitochondrial DNA point mutations." Nucl. Acid. Res. 29(15). 
  
Torroni, A., Stepien, G., Hodge, J., Wallace, D. (1990). "Neoplastic transformation is associated 
with coordinate induction of nuclear and cytoplasmic oxidative phosphorylation genes." J. 
Biol. Chem. 265(33): 20589-20593. 
  
Tryoen-Toth, P., Richerts, S., Sohm, B. (2003). "Proteomic consequences of a human 
mitochondrial tRNA mutation beyond the frame of mitochondrial translation." J. Biol. 
Chem. 278(27): 24314-24323. 
  
Twigg, J., Fulton, N., Gomez, E., Irvine, D., Aitken, R. (1998). "Analysis of the impact of 
intracellular reactive oxygen species generation on the structural and functional integrity of 
human spermatozoa: lipid peroxidation, DNA fragmentation and effectiveness of 
antioxidants." Hum. Reprod. 13(6): 1429-1436. 
  
Uchida, K. (1999). "Current status of acrolein as a lipid peroxidation product." TCM 9(5): 109-113. 
  
Vander Heidan, M., Chandel, N., Li, X., Schumacker, P., Colombini, M., Thompson, C. (2000). 
"Outer mitochondrial membrane permeability can regulate coupled respiration and cell 
survival." PNAS 97(9): 4666-4671. 
  
Vergani, L., Rossi, R., Brierley, H., Hanna, M., Holt, I. (1999). "Introduction of heteroplasmic 
mitochondrial DNA (mtDNA) from a patient with NARP into two human po cell lines is 
associated either with selection and maintenance of NARP mutant mtDNA or failure to 
maintain mtDNA." Hum. Mol. Genet. 8(9): 1751-1755. 
  
Villani, G., Greco, M., Papa, S., Attardi, G. (1998). "Low reserve of cytochrome c oxidase capacity 
in vivo in the respiratory chain of a variety of human cell types." J. Biol. Chem. 273(48): 
31829-31836. 
  
References 
 111
Wallace, D. (1986). "Mitotic segregation of mitochondrial DNAs in human cell hybrids and 
expression of chloramphenicol resistance." Somat. Cell. Mol. Genet. 12(1): 41-49. 
  
Wallace, D., Brown, M., Lott, M. (1999). "Mitochondrial DNA variation in human evolution and 
disease." Gene 238: 211-230. 
  
Wallace, D. C. (1999). "Mitochondrial diseases in man and mouse." Science 283: 1482-1488. 
  
Wang, X., Sharma, R., Sikka, S., Thomas, A., Falcone, T., Agarwal, A. (2003). "Oxidative stress is 
associated with increased apoptosis leading to spermatozoa DNA damage in patients with 
male factor infertility." Fertility and Sterility 80(3): 531-535. 
  
British Broadcasting Corporation, www.bbc.co.uk. 
  
Yasukawa, T., Suzuki, T., Ishii, N., Ohta, S., Watanabe. (2001). "Wobble modification defect in 
tRNA disturbs codon-anticodon interaction in a mitochondrial disease." EMBO J. 20(17): 
4794-4802. 
  
Zhen, Y., Hoganson, C., Babcock, G., Ferguson-miller, S. (1999). "Definition of the interaction 
domain for cytochrome c on cytochrome c oxidase." J. Biol. Chem. 274(53): 38032-38041. 
 
Zini, A., de Lamirande, E. Gagnon, C. 1995. Low levels of nitric oxide promote  human sperm 
capacitation. J. Androl. 16(5): 424-431. 
  
Zivadinovic, D., Gametchu, B., Waston, C. (2004). "Membrane estrogen receptor-alpha levels in 
MCF-7 breast cancer cells predict c AMP and proliferation responses." Breast Cancer 
Research 7(1): 101-112. 
  
Zou, E., Matsumura, F. (2003). "Long-term exposure to beta-hexachlorocyclohexane (beta-HCH) 
promotes transformation and invasiveness of MCF-7 human breast cancer cells." Biochem. 
Pharm. 66: 831-840. 
  
 
Appendices 
ACKNOWLEDGEMENTS 
_____________________________________________________________________ 
 
 
Firstly, to my Lord and King Jesus Christ- anything thats good in me is because of 
you and your great love.  
 
For Mum and Dad, Kelly and Dale who have believed in my abilities and encouraged 
me throughout, thank you, I love you. To all of my friends, workmates and flatmates 
that have been so caring of me and willing to help me in many different ways, 
especially Sarah and Lynette, thank you for your support. To my family at St Johns 
who have prayed for me, encouraged me and helped me to grow and continue to grow, 
especially Ailers, Chris, Sarah, Paula, Sophie, Aidan, Tim, Fiona, Melissa, Peter, 
Wally, and Ruth, who have encouraged me greatly.  
 
Thanks to my supervisors Frank Sin, Steven Gieseg and Dru Mason for their advice 
and in supplying the cultures and equipment. Thank you to Jan McKenzie for her hard 
work and persistence with the inverted microscope and to Linda Morris for her care 
and dedication in managing the genetics lab and the teaching lab. Thanks heaps to the 
Gemmell lab for the farewell drinks! Thank you to all the lab members and in 
particular Maxine Bryant in giving her time to read this thesis and provide helpful 
comments. 
 
